WO2007053181A2 - Chemically tailorable nanoparticles realized through metal-metalloligand coordination chemistry - Google Patents
Chemically tailorable nanoparticles realized through metal-metalloligand coordination chemistry Download PDFInfo
- Publication number
- WO2007053181A2 WO2007053181A2 PCT/US2006/020966 US2006020966W WO2007053181A2 WO 2007053181 A2 WO2007053181 A2 WO 2007053181A2 US 2006020966 W US2006020966 W US 2006020966W WO 2007053181 A2 WO2007053181 A2 WO 2007053181A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- colloidal
- particles
- analyte
- particle
- bmsb
- Prior art date
Links
- 239000002105 nanoparticle Substances 0.000 title description 11
- 239000002245 particle Substances 0.000 claims abstract description 197
- 238000000034 method Methods 0.000 claims abstract description 52
- 230000002194 synthesizing effect Effects 0.000 claims abstract description 3
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 90
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 53
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 45
- 239000012491 analyte Substances 0.000 claims description 45
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 38
- 229910052751 metal Inorganic materials 0.000 claims description 36
- 239000002184 metal Substances 0.000 claims description 34
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 claims description 30
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 27
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 24
- 239000012454 non-polar solvent Substances 0.000 claims description 24
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 23
- 239000003446 ligand Substances 0.000 claims description 20
- 150000003839 salts Chemical class 0.000 claims description 20
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 18
- 150000001875 compounds Chemical class 0.000 claims description 16
- 125000003118 aryl group Chemical group 0.000 claims description 15
- 229910021645 metal ion Inorganic materials 0.000 claims description 15
- 125000000217 alkyl group Chemical group 0.000 claims description 14
- 238000003556 assay Methods 0.000 claims description 14
- 125000001072 heteroaryl group Chemical group 0.000 claims description 14
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 13
- 102000039446 nucleic acids Human genes 0.000 claims description 12
- 108020004707 nucleic acids Proteins 0.000 claims description 12
- 150000007523 nucleic acids Chemical class 0.000 claims description 12
- 229910052725 zinc Inorganic materials 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 9
- 239000011859 microparticle Substances 0.000 claims description 9
- 108090000623 proteins and genes Proteins 0.000 claims description 9
- 229910052802 copper Inorganic materials 0.000 claims description 7
- 230000005291 magnetic effect Effects 0.000 claims description 7
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 7
- 229910052759 nickel Inorganic materials 0.000 claims description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims description 6
- 102000004169 proteins and genes Human genes 0.000 claims description 6
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims description 5
- 229910052748 manganese Inorganic materials 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 5
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 4
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 claims description 4
- 229910052793 cadmium Inorganic materials 0.000 claims description 4
- 229910052804 chromium Inorganic materials 0.000 claims description 4
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 claims description 4
- 229910052745 lead Inorganic materials 0.000 claims description 4
- 238000005406 washing Methods 0.000 claims description 3
- 239000000126 substance Substances 0.000 abstract description 14
- 239000013256 coordination polymer Substances 0.000 abstract description 5
- 229920001795 coordination polymer Polymers 0.000 abstract description 5
- 239000000523 sample Substances 0.000 description 46
- 238000001514 detection method Methods 0.000 description 34
- 239000000243 solution Substances 0.000 description 24
- -1 e.g. Chemical group 0.000 description 23
- 239000000203 mixture Substances 0.000 description 22
- 125000003729 nucleotide group Chemical group 0.000 description 22
- 108091033319 polynucleotide Proteins 0.000 description 22
- 239000002157 polynucleotide Substances 0.000 description 22
- 102000040430 polynucleotide Human genes 0.000 description 22
- 238000006243 chemical reaction Methods 0.000 description 21
- 108020004414 DNA Proteins 0.000 description 19
- 108091034117 Oligonucleotide Proteins 0.000 description 18
- 239000002773 nucleotide Substances 0.000 description 16
- 239000000047 product Substances 0.000 description 16
- 238000012544 monitoring process Methods 0.000 description 13
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- 230000015572 biosynthetic process Effects 0.000 description 11
- 150000007942 carboxylates Chemical class 0.000 description 11
- 238000000399 optical microscopy Methods 0.000 description 11
- 239000002243 precursor Substances 0.000 description 11
- 239000002904 solvent Substances 0.000 description 11
- 230000009870 specific binding Effects 0.000 description 11
- 239000012798 spherical particle Substances 0.000 description 11
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 10
- 238000005341 cation exchange Methods 0.000 description 10
- 238000009396 hybridization Methods 0.000 description 10
- 239000002751 oligonucleotide probe Substances 0.000 description 10
- 239000000427 antigen Substances 0.000 description 9
- 108091007433 antigens Proteins 0.000 description 9
- 102000036639 antigens Human genes 0.000 description 9
- 238000005160 1H NMR spectroscopy Methods 0.000 description 8
- 150000002500 ions Chemical class 0.000 description 8
- 239000008188 pellet Substances 0.000 description 8
- 238000004626 scanning electron microscopy Methods 0.000 description 8
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 description 7
- 238000005481 NMR spectroscopy Methods 0.000 description 7
- 150000004753 Schiff bases Chemical class 0.000 description 7
- 230000027455 binding Effects 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 239000007789 gas Substances 0.000 description 7
- 230000003993 interaction Effects 0.000 description 7
- 229910014033 C-OH Inorganic materials 0.000 description 6
- 229910014570 C—OH Inorganic materials 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 239000002262 Schiff base Substances 0.000 description 6
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 6
- 238000002296 dynamic light scattering Methods 0.000 description 6
- 238000000295 emission spectrum Methods 0.000 description 6
- 239000003570 air Substances 0.000 description 5
- 230000003321 amplification Effects 0.000 description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 238000003199 nucleic acid amplification method Methods 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 238000001228 spectrum Methods 0.000 description 5
- 230000009466 transformation Effects 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- 125000003545 alkoxy group Chemical group 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 4
- 238000009792 diffusion process Methods 0.000 description 4
- 238000000799 fluorescence microscopy Methods 0.000 description 4
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 4
- 125000005843 halogen group Chemical group 0.000 description 4
- 239000002207 metabolite Substances 0.000 description 4
- 238000006116 polymerization reaction Methods 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 238000001878 scanning electron micrograph Methods 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 125000003396 thiol group Chemical group [H]S* 0.000 description 4
- 108090001008 Avidin Proteins 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- WAEMQWOKJMHJLA-UHFFFAOYSA-N Manganese(2+) Chemical compound [Mn+2] WAEMQWOKJMHJLA-UHFFFAOYSA-N 0.000 description 3
- 108010090804 Streptavidin Proteins 0.000 description 3
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 3
- 230000002776 aggregation Effects 0.000 description 3
- 238000004220 aggregation Methods 0.000 description 3
- 229930013930 alkaloid Natural products 0.000 description 3
- 239000012080 ambient air Substances 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000001124 body fluid Anatomy 0.000 description 3
- 239000010839 body fluid Substances 0.000 description 3
- 150000001732 carboxylic acid derivatives Chemical group 0.000 description 3
- 238000006555 catalytic reaction Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical class O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 125000000753 cycloalkyl group Chemical group 0.000 description 3
- 238000000921 elemental analysis Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 238000001506 fluorescence spectroscopy Methods 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 231100001261 hazardous Toxicity 0.000 description 3
- 150000002430 hydrocarbons Chemical group 0.000 description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 150000002739 metals Chemical class 0.000 description 3
- 125000002950 monocyclic group Chemical group 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical class O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 230000000704 physical effect Effects 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 3
- 238000012372 quality testing Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 239000012808 vapor phase Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- CDAWCLOXVUBKRW-UHFFFAOYSA-N 2-aminophenol Chemical compound NC1=CC=CC=C1O CDAWCLOXVUBKRW-UHFFFAOYSA-N 0.000 description 2
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 2
- 229930024421 Adenine Natural products 0.000 description 2
- BWKDAAFSXYPQOS-UHFFFAOYSA-N Benzaldehyde glyceryl acetal Chemical compound O1CC(O)COC1C1=CC=CC=C1 BWKDAAFSXYPQOS-UHFFFAOYSA-N 0.000 description 2
- 206010006326 Breath odour Diseases 0.000 description 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 2
- GSNUFIFRDBKVIE-UHFFFAOYSA-N DMF Natural products CC1=CC=C(C)O1 GSNUFIFRDBKVIE-UHFFFAOYSA-N 0.000 description 2
- 108091093037 Peptide nucleic acid Proteins 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 2
- 108091028664 Ribonucleotide Proteins 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 159000000021 acetate salts Chemical class 0.000 description 2
- 125000004442 acylamino group Chemical group 0.000 description 2
- 229960000643 adenine Drugs 0.000 description 2
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 2
- 125000003282 alkyl amino group Chemical group 0.000 description 2
- 125000004644 alkyl sulfinyl group Chemical group 0.000 description 2
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 2
- 125000004414 alkyl thio group Chemical group 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 230000001588 bifunctional effect Effects 0.000 description 2
- 238000004166 bioassay Methods 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 2
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 239000000356 contaminant Substances 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 229940104302 cytosine Drugs 0.000 description 2
- 239000005547 deoxyribonucleotide Substances 0.000 description 2
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000003344 environmental pollutant Substances 0.000 description 2
- 239000002360 explosive Substances 0.000 description 2
- 239000000446 fuel Substances 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 239000007792 gaseous phase Substances 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 238000002329 infrared spectrum Methods 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000009871 nonspecific binding Effects 0.000 description 2
- 238000000879 optical micrograph Methods 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- WXHIJDCHNDBCNY-UHFFFAOYSA-N palladium dihydride Chemical compound [PdH2] WXHIJDCHNDBCNY-UHFFFAOYSA-N 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 231100000719 pollutant Toxicity 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- LOUPRKONTZGTKE-LHHVKLHASA-N quinidine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-LHHVKLHASA-N 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 239000002336 ribonucleotide Substances 0.000 description 2
- 125000002652 ribonucleotide group Chemical group 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 239000002689 soil Substances 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 238000000844 transformation Methods 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 239000008096 xylene Substances 0.000 description 2
- 150000003738 xylenes Chemical class 0.000 description 2
- FANCTJAFZSYTIS-IQUVVAJASA-N (1r,3s,5z)-5-[(2e)-2-[(1r,3as,7ar)-7a-methyl-1-[(2r)-4-(phenylsulfonimidoyl)butan-2-yl]-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol Chemical compound C([C@@H](C)[C@@H]1[C@]2(CCCC(/[C@@H]2CC1)=C\C=C\1C([C@@H](O)C[C@H](O)C/1)=C)C)CS(=N)(=O)C1=CC=CC=C1 FANCTJAFZSYTIS-IQUVVAJASA-N 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 240000005020 Acaciella glauca Species 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- KZFBHCCLJSAHBQ-UHFFFAOYSA-N Benzoylecgonine Natural products CN1C2CCC1C(C(C2)OC(=C)c3ccccc3)C(=O)O KZFBHCCLJSAHBQ-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 0 CC(C1c2c(*)c(C=Nc3cc(C(O)=O)ccc3O)cc3c2cccc3)C(C=N[C@@]2C=C(CC(O)=O)C=CC2O)=Cc2c1cccc2 Chemical compound CC(C1c2c(*)c(C=Nc3cc(C(O)=O)ccc3O)cc3c2cccc3)C(C=N[C@@]2C=C(CC(O)=O)C=CC2O)=Cc2c1cccc2 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 241000272194 Ciconiiformes Species 0.000 description 1
- 235000001258 Cinchona calisaya Nutrition 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical group O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 108010008177 Fd immunoglobulins Proteins 0.000 description 1
- 208000001836 Firesetting Behavior Diseases 0.000 description 1
- OZLGRUXZXMRXGP-UHFFFAOYSA-N Fluo-3 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=C(C=2)C2=C3C=C(Cl)C(=O)C=C3OC3=CC(O)=C(Cl)C=C32)N(CC(O)=O)CC(O)=O)=C1 OZLGRUXZXMRXGP-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 208000032139 Halitosis Diseases 0.000 description 1
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 description 1
- 102000006947 Histones Human genes 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- ZAGRKAFMISFKIO-UHFFFAOYSA-N Isolysergic acid Natural products C1=CC(C2=CC(CN(C2C2)C)C(O)=O)=C3C2=CNC3=C1 ZAGRKAFMISFKIO-UHFFFAOYSA-N 0.000 description 1
- MKXZASYAUGDDCJ-SZMVWBNQSA-N LSM-2525 Chemical compound C1CCC[C@H]2[C@@]3([H])N(C)CC[C@]21C1=CC(OC)=CC=C1C3 MKXZASYAUGDDCJ-SZMVWBNQSA-N 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000029797 Prion Human genes 0.000 description 1
- 108091000054 Prion Proteins 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 102100035254 Sodium- and chloride-dependent GABA transporter 3 Human genes 0.000 description 1
- 101710104417 Sodium- and chloride-dependent GABA transporter 3 Proteins 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 229910007339 Zn(OAc)2 Inorganic materials 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229940072049 amyl acetate Drugs 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- PGMYKACGEOXYJE-UHFFFAOYSA-N anhydrous amyl acetate Natural products CCCCCOC(C)=O PGMYKACGEOXYJE-UHFFFAOYSA-N 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000002528 anti-freeze Effects 0.000 description 1
- 230000009830 antibody antigen interaction Effects 0.000 description 1
- 230000009833 antibody interaction Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 150000004982 aromatic amines Chemical class 0.000 description 1
- 239000010953 base metal Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000012867 bioactive agent Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- OSVHLUXLWQLPIY-KBAYOESNSA-N butyl 2-[(6aR,9R,10aR)-1-hydroxy-9-(hydroxymethyl)-6,6-dimethyl-6a,7,8,9,10,10a-hexahydrobenzo[c]chromen-3-yl]-2-methylpropanoate Chemical compound C(CCC)OC(C(C)(C)C1=CC(=C2[C@H]3[C@H](C(OC2=C1)(C)C)CC[C@H](C3)CO)O)=O OSVHLUXLWQLPIY-KBAYOESNSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- UHYPYGJEEGLRJD-UHFFFAOYSA-N cadmium(2+);selenium(2-) Chemical compound [Se-2].[Cd+2] UHYPYGJEEGLRJD-UHFFFAOYSA-N 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- XLJKHNWPARRRJB-UHFFFAOYSA-N cobalt(2+) Chemical compound [Co+2] XLJKHNWPARRRJB-UHFFFAOYSA-N 0.000 description 1
- 229960003920 cocaine Drugs 0.000 description 1
- 229960004126 codeine Drugs 0.000 description 1
- 238000000319 cold-field-emission scanning electron microscopy Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- NWFNSTOSIVLCJA-UHFFFAOYSA-L copper;diacetate;hydrate Chemical compound O.[Cu+2].CC([O-])=O.CC([O-])=O NWFNSTOSIVLCJA-UHFFFAOYSA-L 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000005564 crystal structure determination Methods 0.000 description 1
- 239000002178 crystalline material Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 238000001446 dark-field microscopy Methods 0.000 description 1
- 238000013500 data storage Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 229960001985 dextromethorphan Drugs 0.000 description 1
- 230000005292 diamagnetic effect Effects 0.000 description 1
- 229960002069 diamorphine Drugs 0.000 description 1
- 239000002283 diesel fuel Substances 0.000 description 1
- UZBQIPPOMKBLAS-UHFFFAOYSA-N diethylazanide Chemical compound CC[N-]CC UZBQIPPOMKBLAS-UHFFFAOYSA-N 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229930002995 diterpene alkaloid Natural products 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 238000000132 electrospray ionisation Methods 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 238000000119 electrospray ionisation mass spectrum Methods 0.000 description 1
- 238000004993 emission spectroscopy Methods 0.000 description 1
- 238000004836 empirical method Methods 0.000 description 1
- 238000002149 energy-dispersive X-ray emission spectroscopy Methods 0.000 description 1
- 238000000724 energy-dispersive X-ray spectrum Methods 0.000 description 1
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 231100000613 environmental toxicology Toxicity 0.000 description 1
- 229960003133 ergot alkaloid Drugs 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000002073 fluorescence micrograph Methods 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000004345 fruit ripening Effects 0.000 description 1
- 239000002316 fumigant Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 238000007499 fusion processing Methods 0.000 description 1
- 239000003502 gasoline Substances 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 125000004438 haloalkoxy group Chemical group 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 239000013056 hazardous product Substances 0.000 description 1
- 239000002920 hazardous waste Substances 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-M heptanoate Chemical compound CCCCCCC([O-])=O MNWFXJYAOYHMED-UHFFFAOYSA-M 0.000 description 1
- 125000004404 heteroalkyl group Chemical group 0.000 description 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 1
- 238000007172 homogeneous catalysis Methods 0.000 description 1
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229920000592 inorganic polymer Polymers 0.000 description 1
- 229940030980 inova Drugs 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 229930013397 isoquinoline alkaloid Natural products 0.000 description 1
- 125000002183 isoquinolinyl group Chemical class C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- ZAGRKAFMISFKIO-QMTHXVAHSA-N lysergic acid Chemical compound C1=CC(C2=C[C@H](CN([C@@H]2C2)C)C(O)=O)=C3C2=CNC3=C1 ZAGRKAFMISFKIO-QMTHXVAHSA-N 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- 238000007885 magnetic separation Methods 0.000 description 1
- 239000006148 magnetic separator Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 238000006263 metalation reaction Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 229930013053 morphinan alkaloid Natural products 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 239000003345 natural gas Substances 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 230000001293 nucleolytic effect Effects 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 125000002524 organometallic group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 239000001301 oxygen Chemical group 0.000 description 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- 230000005298 paramagnetic effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-M perchlorate Inorganic materials [O-]Cl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-M 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 229920001308 poly(aminoacid) Polymers 0.000 description 1
- 230000000379 polymerizing effect Effects 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000001144 powder X-ray diffraction data Methods 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 150000003139 primary aliphatic amines Chemical class 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000003498 protein array Methods 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 229930002339 quinazoline alkaloid Natural products 0.000 description 1
- 125000002294 quinazolinyl group Chemical class N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 229960001404 quinidine Drugs 0.000 description 1
- 229960000948 quinine Drugs 0.000 description 1
- 229930002341 quinoline alkaloid Natural products 0.000 description 1
- 150000003248 quinolines Chemical class 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 235000003499 redwood Nutrition 0.000 description 1
- 238000000985 reflectance spectrum Methods 0.000 description 1
- 239000003507 refrigerant Substances 0.000 description 1
- 238000005067 remediation Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 239000010802 sludge Substances 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 229930003352 steroid alkaloid Natural products 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229960002317 succinimide Drugs 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000003104 tissue culture media Substances 0.000 description 1
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 1
- 238000001392 ultraviolet--visible--near infrared spectroscopy Methods 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 238000000733 zeta-potential measurement Methods 0.000 description 1
- DJWUNCQRNNEAKC-UHFFFAOYSA-L zinc acetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O DJWUNCQRNNEAKC-UHFFFAOYSA-L 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F1/00—Compounds containing elements of Groups 1 or 11 of the Periodic Table
- C07F1/005—Compounds containing elements of Groups 1 or 11 of the Periodic Table without C-Metal linkages
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y15/00—Nanotechnology for interacting, sensing or actuating, e.g. quantum dots as markers in protein assays or molecular motors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
- C07F15/04—Nickel compounds
- C07F15/045—Nickel compounds without a metal-carbon linkage
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F3/00—Compounds containing elements of Groups 2 or 12 of the Periodic Table
- C07F3/003—Compounds containing elements of Groups 2 or 12 of the Periodic Table without C-Metal linkages
Definitions
- Micro- and nano-sized particles play important roles in many different areas, including catalysis, optics, biosensing, and data storage. Recent advances in this field have made it possible to control many of the chemical and physical properties of these solid-state materials through control over their size, shape, and composition. (Peng, et al. Nature 404:59 (2000); Horn et al., Angew. Chem. Int. Ed. 40:4331 (2001); and Chen et al. Angew. Ckem. Int. Ed. 44:2589 (2005)).
- One important goal in this area is an ability to intentionally interconvert different particle compositions and structures through chemistry that occurs throughout the particle structure, in addition to chemistry on its surface.
- colloidal particles comprising metal-organic coordination polymers.
- the colloidal particles are assembled from a coordination of a metal salt and bis- metallo-tridentate Schiff base (BMSB) building blocks.
- BMSB bis- metallo-tridentate Schiff base
- the colloidal particles of the present invention have a formula (I) or (II):
- R 1 is independently selected from the group consisting of H, hydroxyl, C 1-8 alkyl, OC 1-8 alkyl, Ci -8 heteroalkyl, OC 1-8 heteroalkyl, P(R 2 ) 2 , ary ⁇ , heteroaryl;
- R 2 is the same or different and is selected from aryl or heteroaryl;
- R 3 is independently selected from the group consisting of H, hydroxyl, C 1-8 alkyl, OCi -8 alkyl, C 1-8 heteroalkyl, OC 1-8 heteroalkyl, P(R 2 ) 2 , aryl, heteroaryl;
- M and M' are independently selected from the group consisting of Zn, Cu, Mn, Pb, Ni, Cd, Co, and Cr;
- L is null or a ligand selected from the group consisting of pyridine, methanol, acetate, dimethylsulfoxide, dimethylformamide, acetone, water, chloride, fluoride, iodide,
- a method of synthesizing the colloidal particles wherein a metal salt solution and BMSB are admixed, then a nonpolar solvent is added to the admixture.
- a nonpolar solvent are pentane, diethyl ether, hexane, benzene, xylenes, cyclohexane, and toluene.
- the nonpolar solvent is added rapidly to the mixture of metal salt and BMSB, and the resulting colloidal particles have a diameter of about 100 to less than 1 ⁇ m.
- the nonpolar solvent is added slowly, and the resulting colloidal particles have a diameter of about 1 ⁇ m to about 5 ⁇ m.
- a sample containing or suspected of containing an analyte of interest is mixed with (1) a magnetic microparticle (MMP) which is modified with a tag. on its surface that is specific for the analyte and (2) a colloidal particle of the present invention which is modified with a tag on its surface that is specific for the analyte.
- MMP magnetic microparticle
- a sandwich structure of MMP-analyte-colloidal particle results, and is isolated, e.g., using a magnet.
- the sandwich structure then is dissolved in pyridine, and a fluorescence is measured. The fluorescence is correlated to the presence or concentration of the analyte of interest.
- the colloidal particles comprise Zn.
- FIG. 1 shows a schematic of the preparation of colloidal particles of the invention from metal salts and bis-metallo-tridentate Schiff base (BMSB) building blocks;
- FIG. 2 shows images, of colloidal particles prepared by the disclosed methods and analyzed by (a) optical microscopy, (b) and (c) fluorescence microscopy, and (d) scanning electron microscopy (SEM) where the inset in (d) is a high-resolution zoom-in image of the colloidal particles;
- FIG. 4 shows emission spectra (excitation wavelength of 420 nm) of Zn-BMSB-Zn particles where the ancillary ligands have been systematically changed to dimethyl sulfoxide (DMSO), pyridine, dimethylformamide, acetone, methanol, or water;
- DMSO dimethyl sulfoxide
- pyridine dimethylformamide
- acetone acetone
- methanol or water
- FIG. 5 shows a schematic of selective cation exchange of disclosed colloidal particles, where mixture of a colloidal particle and a metal salt (M") allows for the exchange of the M' ion of the colloidal particle to the M" ion, while the M ion remains unaffected;
- M metal salt
- FIG. 6 shows the chemical transformation of Zn-BMSB-Zn colloidal particles to Cu-BMSB-Zn particles via cation exchange, where (a) shows both the optical microscopy (OM, top) and fluorescence microscopy (FM, bottom) images of the mixture at time 0, (b) is at time 1 minute, (c) time 5 minutes, and (d) at time 60 minutes, (e) is a photograph of Zn- BMSB-Zn (right) and Cu-BMSB-Zn (left), and (f) is an emission spectra obtained by exciting at 420 nm;
- FIG. 7 shows SEM images of (a) Zn-BMSB-Zn and (b) Cu-BMSB-Zn, where the scale bars indicate 5 ⁇ m;
- FIG. 8 shows OM and FM (inset) images of (a) Zn-BMSB-Zn, (b) Cu-BMSB-Zn, (c) Mn-BMSB-Zn, and (d) Pb-BMSB-Zn, and (e) and (f) are photographs of, from left to right, Zn-BMSB-Zn, Cu-BMSB-Zn, Mn-BMSB-Zn, and Pb-BMSB-Zn, where (f) in with UV-irradation, indicating that only Zn-BMSB-Zn is fluorescent;
- FIG. 9 shows a schematic of an analyte detection method using the colloidal- particles disclosed herein where a capture DNA-modified magnetic probe is mixed with a target DNA and a fluorescent colloidal particle further modified with a capture DNA to form a "sandwich" of the magnetic probe-target DNA-colloidal particle (step 1) and then isolated using a magnetic field (step 2), and dissolved with pyridine to create an amplified fluorescence signal (step 3); and
- FIG. 10 shows (a) fluorescence spectroscopy of solution of colloidal particles dissolved in pyridine as a function of target DNA concentration in PBS buffer, and (b) shows fluorescence intensity of the particles quantified by integration of the area of the spectra from 580 to 615 nm for target DNA concentrations from 5 aM to 50 fM.
- colloidal particles of polymerized metal-ligand networks made by coordination-chemistry-induced assembly of metal ions and carboxylate functionalized bis-metallo-tridentate Schiff base (BMSB) building blocks (FIG. 1).
- the colloidal particles are formed by the polymerization of the BMSB and metal, ions, and the size of the colloidal particles can be controlled by the manner in which the BMSB and metal ions are mixed together.
- Colloidal particles of the present invention have a formula (I) or (II):
- R 1 is independently selected from the group consisting of H, hydroxy!, C 1-8 alkyl, C 1-8 alkoxy, C 1-8 heteroalkyl, OC 1-8 heteroalkyl, P(R 2 ) 2 , aryl, heteroaryl;
- R 2 is the same or different and is selected from aryl or heteroaryl;
- R 3 is independently selected from the group consisting of H, hydroxyl, C 1-8 alkyl, OC 1-8 alkyl, C 1-8 heteroalkyl, OC 1-8 heteroalkyl, P(R 2 ) 2 , aryl, heteroaryl;
- M and M' are independently selected from the group consisting of Zn, Cu, Mn, Pb, Ni, Cd, Co, and Cr;
- L is null or a ligand selected from the group consisting of pyridine, methanol, acetate, dimethylsulfoxide, dimethylformamide, acetone, water, chloride, fluoride, iodide, bromid
- alkyl includes straight chained and branched hydrocarbon groups containing the indicated number of carbon atoms, such as methyl, ethyl, and straight chain and branched propyl and butyl groups.
- the hydrocarbon group can contain up to 8 carbon atoms.
- alkyl also encompasses alkyl groups which are optionally substituted with, e.g., one or more halogen atoms, one or more hydroxyl groups, or one or more thiol groups. Also encompassed by the term “alkyl” are cycloalkyl groups.
- Cycloalkyl is defined as a cyclic C 3 -C 8 hydrocarbon group, e.g., cyclopropyl, cyclobutyl, cyclohexyl, and cyclopentyl.
- Heteroalkyl and “heterocycloalkyl” are defined similar to alkyl and cycloalkyl, except at least one heteroatom is present in the structure. Suitable heteroatoms include N, S, and O.
- halo or halogen is defined herein to include fluorine, bromine, chlorine, and iodine.
- aryl groups include phenyl, naphthyl, tetrahydronaphthyl, 2-chlorophenyl, 3-chloropheny.l, 4-chlorophenyl, 2- methylphenyl, 4-methoxyphenyl, 3-trifluoromethylphenyl, 4-nitrophenyl, and the like.
- arylC 1-3 alkyl and “heteroarylC 1-3 alkyl” are defined as an aryl or heteroaryl group having a C 1-3 alkyl substituent.
- heteroaryl is defined herein as a monocyclic or bicyclic ring system containing one or two aromatic rings and containing at least one nitrogen, oxygen, or sulfur atom in an aromatic ring, and which can be unsubstituted or substituted, for example, with one or more, and in particular one to three, substituents, like halo, alkyl, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, haloalkyl, nitro, amino, alkylamino, acylamino, alkylthio, alkylsulfinyl, and alkylsulfonyl.
- heteroaryl groups include thienyl, furyl, pyridyl, oxazolyl, quinolyl, isoquinolyl, indolyl, triazolyl, isothiazolyl, isoxazolyl, imidizolyl, benzothiazolyl, pyrazinyl, pyrimidinyl, thiazolyl, and thiadiazolyl.
- hydroxy is defined as -OH.
- alkoxy is defined as -OR, wherein R is alkyl.
- Colloidal particles of the present invention have a diameter of about 100 nm to about 5 ⁇ m, which is dependent upon the manner in which the colloidal particles are prepared.
- a nonpolar solvent such as, e.g., diethyl ether or pentane
- the result is smaller diameter colloidal particles, while the slow addition of the nonpolar solvent results in larger diameter colloidal particles.
- BMSB molecules can be prepared through known chemical techniques. One such technique is outlined in the following scheme for the formation of a specific, nonlimiting BMSB.
- BMSBs can be prepared by altering the starting di-aldehyde, aromatic amine, and/or metal salt.
- the BMSB is then used to prepare the colloidal particles of the present invention.
- the BMSB building blocks are important components of the strategy for making the colloidal particles disclosed herein. They are readily polymerizable through their carboxylate groups and allow manipulation of the chemical and physical properties of the resulting colloidal particles in a systematic manner through choice of BMSB ligand, type of metallation, and ancillary ligands.
- the BMSB is mixed with a metal * salt (such as, e.g., M' (OAc) 2 ) in a pyridine solution.
- the metal of the BMSB may be the same or different from the metal salt used.
- the colloidal particles are prepared by the addition, either fast (to form smaller diameter colloidal particles) or slow (to form larger diameter colloidal particles), of a nonpolar solvent.
- the nonpolar solvent typically pentane or diethyl ether, affects the solubility of the forming colloidal particle.
- the fast addition of the nonpolar solvent causes the forming colloidal particle to precipitate out of solution more quickly, and the resulting colloidal particles are therefore smaller in diameter.
- Slow addition of the nonpolar solvent allows for the colloidal particles to grow in solution for a longer period of time before precipitating out of solution, and, therefore, have larger diameters than those produced from the fast addition of the nonpolar solvent.
- the nonpolar solvent used also effects the size of the resulting colloidal particles.
- Diethyl ether typically provides smaller diameter colloidal particles, whereas pentane provides larger diameter colloidal particles under the same conditions.
- the fast addition of diethyl ether results in colloidal particles having a diameter of about 190 ⁇ 60 rnn
- fast addition of pentane results in colloidal particles having a diameter of about 780 ⁇ 230 nm.
- Slow addition of diethyl ether results in colloidal particles having a diameter of about 1.60 ⁇ 0.47 ⁇ m
- slow addition of pentane results in colloidal particles having a diameter of about 5 ⁇ m.
- colloidal particle diameter can be controlled through the appropriate choice of nonpolar solvent and rate of addition of the nonpolar solvent to the mixture of BMSB and metal salt.
- the polarity of the solvent affects the solubility of the resulting colloidal particles and, therefore, their average size.
- FIG. 2 When pentane is used as an initiation solvent instead of diethyl ether, larger spherical microp articles (5 ⁇ 3 ⁇ m) are formed (FIG. 2).
- the growth of the particles under this set of conditions can be observed by taking aliquots at various stages and characterizing the particles by SEM and OM.
- This set of experiments also provides some mechanistic insight into the particle growth process.
- clusters of smaller particles are observable (FIG. 2 A and 2D). These structures slowly anneal into single particles having smoother surfaces (FIG.
- the proposed mechanism of the formation of the structures is via a two step cluster-fusion growth process (FIG. 2E).
- the first step is aggregation of several small particles to form large cluster particles.
- the second step is intraparticle fusion, resulting in large uniform spherical particles. This can occur because of the reversible nature of the metal coordination chemistry, which allows the system to anneal into a smooth particle.
- the cluster fusion step can involve a plurality of particles or only a few, depending upon conditions, and the ultimate size of the large spherical particles depends upon the number of smaller particles involved in the fusion process.
- the phrase "rapid addition,” or interchangeably “fast addition,” means herein that the nonpolar solvent is added to the mixture at a rate of at least 1 mL/sec, preferably at least 3 mL/sec, and most preferably at least 5 mL/sec.
- the phrase “slow addition” means herein that the nonpolar solvent is added to the mixture at a rate of less than 1 mL/sec, preferably less than 1 mL/min, and most preferably, less than 1 mL/hour.
- nonpolar solvent means a solvent which is immiscible or only slightly miscible in pyridine.
- solubility parameter a solvent which is immiscible or only slightly miscible in pyridine.
- Solvents with solubility parameters ( ⁇ ) of less than 19.0 can be used in the methods disclosed herein, more preferably less than 18.0, and most preferably less than 16.0.
- Pentane has a solubility parameter of 14.4
- diethyl ether has a solubility parameter of 15.4
- toluene a solubility parameter of 18.3.
- Solubility parameters can be found in any chemistry handbook, such as, e.g., Barton, Handbook of Solubility Parameters, CRC Press (1983).
- Other examples of nonpolar solvents include benzene, xylenes, hexanes, cyclohexane, amyl acetate, and the like.
- the physical properties of the colloidal particles can be affected both by the manner in which they are synthesized, as. discussed above, but also by the ancillary ligand, L, of the colloidal particle.
- the ancillary ligand of the colloidal particles can be changed by mixing the colloidal particle with various solvents. For example, a red toluene suspension of colloidal particles 3a (FIG. 1), (M and M' are Zn, L is pyridine, and the BMSB is a compound of formula (I), where R 1 is null) turns yellow when methanol is added. This color change is attributable to the replacement of the pyridine ligand on the Zn metal centers with methanol.
- the solvent can be removed from this complex and the resulting powder redispersed in toluene having 10% dimethylsulfoxide (DMSO).
- DMSO dimethylsulfoxide
- the yellow solution turns red due to the formation of a zinc-DMSO adduct.
- the emission spectra of colloidal particles having Zn metal centers and various ancillary ligands is shown in FIG. 4, where the ancillary ligand is DMSO, DMF, acetone, methanol, pyridine, or water.
- the ancillary ligand can be easily altered by simple addition of the appropriate small molecule, and is completely reversible, with the exception of pyridine which dissolves the colloidal particle into its BMSB and metal salt components.
- an initiation solvent such as diethyl ether or pentane results in the spontaneous formation of spherical inorganic polymer particles 3 (FIG. 1).
- These particles form via coordination of the carboxylate groups on the BMSB precursor with the metal ions supplied by the acetate salt, and the polymerization process is completely reversible as evidenced by the formation of the starting materials upon addition of excess pyridine.
- Spherical microscale colloidal particles are formed, instead of a macroscopic polymeric material of other reported organometallic polymerizations, due to the slow diffusion of a nonpolar solvent in the pyridine solution of the BMSB and metal salt at room temperature.
- the addition of diethyl ether or pentane to the polar (e.g., pyridine) precursor solution results in precipitation due to the low solubility of the particles in nonpolar media.
- the resulting particles are stable in organic solvents (toluene, methanol, DMF and dimethyl sulfoxide (DMSO)), water, and in the dried state.
- Optical microscopy (OM, FIG. IA), fluorescence microscopy (FM, FIG. 1, B and C), and scanning electron microscopy (SEM, FIG. ID) images of example compositions show the spherical particles with an average diameter of 1.6 ⁇ 1.2 ⁇ m.
- the chemical composition of the particles was determined by energy dispersive X-ray spectroscopy (EDX) and elemental analysis.
- EDX energy dispersive X-ray spectroscopy
- Control experiments with a BMSB which does not contain a free carboxylate group (2d in FIG. 1) show that the coordination polymer and therefore colloidal particles as disclosed herein will not form in the absence of the carboxylate groups.
- Colloidal particles of the present invention can be prepared with a variety of different metals, including Zn, Cu ⁇ Ni, Pd, and Mn, by the choice of starting metal salt and starting BMSB.
- Spherical nanoparticles of Cu-BMSB-Cu 3b (FIG. 1) synthesized by fast addition of pentane into a precursor solution having Cu-BMSB 2b and Cu(OAc) 2 -(H 2 O) Ib in pyridine have diameters similar to Zn-BMSB-Zn particles prepared via analogous procedures. Slow diffusion of pentane into a precursor solution containing 2b and Ib yields particles that are on average significantly larger than the particles formed from the fast addition method.
- Ni-BMSB 2c and Ni(OAc) 2 -4(H2O) Ic gives spherical particles Ni-BMSB-Ni 3c.
- particle compositions of 3b and 3c are not fluorescent because they are not made of fluorescent BMSB building blocks.
- the synthetic methods disclosed herein provide dispersible micro- and nano-scale particles having highly tailorable physical and chemical properties, which can be controlled through choice of polymerizing metal ion, such as Zn(II), Cu(II), or Ni(II), BMSB, and ancillary ligands. Because certain BMSB building blocks can be prepared in enantiopure form (such as, e.g., those based upon a bi-naphthyl ring system) and are important compounds in homogeneous catalysis, this new class of material has great potential in asymmetric catalysis and chiral separations.
- the approach utilizes two different types of ions, ones coordinated to the tridentate pockets of the BMSB ligands and ones that link the BMSB ligands thorough the carboxylate groups to form the polymers.
- Zn(II) is used as the metal ion, it can be readily displaced from the BMSB tridentate pockets, but not from the carboxylate sites with a variety of metal ions (FIG. 5).
- the cation exchange reaction rate is size dependent. Particles of about 200 nm undergo Cu(II) exchange reaction in a few minutes as compared to the hour required to effect it with the micron-scale particles. Again, FM and OM images clearly show the transformation with a minimal change in particle size; the average particle sizes measured before (212 nm) and after the cation exchange reaction (215 nm) by dynamic light scattering (DLS) are nearly identical (FIG. 8A vs. FIG. 8B).
- metal salts can be used to exchange with the metal M of formulae (I) or (II).
- Mn(II), Pb(II), Ni(II), Co(II) and Cu(II) are examples of such suitable metal ions, but metal salts of other metals, or of the same metals but alternative oxidation states (such as, e.g., Mn(IV)) are also contemplated.
- the associated anion of the metal salt is preferably one which is not strongly coordinated to the metal center and can be replaced by alternate coordinating groups, such as, e.g., Schiff bases of the BMSB ligand moieties.
- Such anions include acetate, trifluoroacetate, halide, nitrate, perchlorate, phosphate, sulfate, triflate, and the like.
- the BMSB-metal moiety is a well-known catalytic center, and the colloidal particles can be used as catalysts in the same manner as a typical Schiff base-metal complex can be used. See, for instance, Desimoni et al, Chem. Rev., 103(8): 3119 (2003) and McManus, et al., Chem. i?ev.,104(9): 4151 (2004), each of which is incorporated herein in its entirety.
- the colloidal particles disclosed herein can be used in biological and chemical detection of analytes. Because the colloidal particles are composed of hundred or thousands of fluorescent monomers (such as, e.g., colloidal particles of Zn-BMSB-Zn), minute quantities of an analyte of interest can be detected. The fluorescence of the colloidal particle is amplified by the dissolution of the colloidal particle into its monomelic components. Concentrations as low as about 50 aM (10 "18 M) of analyte are detectable using the colloidal particles disclosed herein. (FIG. 10)
- colloidal particles disclosed herein can be used in "sandwich” type assays.
- assays include, but are not limited to, ELISA, immunoassays using antibody-antigen- antibody interactions, magnetic microparticle (MMP) sandwich assays, and the like, wherein one component of the sandwich assay is modified to incorporate a colloidal particle as disclosed herein.
- MMP magnetic microparticle
- a probe can be attached to the colloidal particle.
- exemplary probes are antibodies, antigens, polynucleotides, oligonucleotides, receptors, ligands, and the like.
- polynucleotide is used broadly herein to mean a sequence of deoxyribonucleotides or ribonucleotides that are linked together by a phosphodiester bond.
- oligonucleotide is used herein to refer to a polynucleotide that is used as a primer or a probe.
- an oligonucleotide useful as a probe or primer that selectively hybridizes to a selected nucleotide sequence is at least about 10 nucleotides in length, usually at least about 15 nucleotides in length, and for example between about 15 and about 50 nucleotides in length.
- Polynucleotide probes are particularly useful for detecting complementary polynucleotides in a biological sample.
- a polynucleotide can be RNA or can be DNA, which can be a gene or a portion thereof, a cDNA, a synthetic polydeoxyribonucleic acid sequence, or the like, and can be single stranded or double stranded, as well as a DNA/RNA hybrid.
- a polynucleotide, including an oligonucleotide e.g., a probe or a primer
- nucleotides comprising a polynucleotide are naturally occurring deoxyribonucleotides, such as adenine, cytosine, guanine or thymine linked to T- deoxyribose, or ribonucleotides such as adenine, cytosine, guanine or uracil linked to ribose.
- a polynucleotide or oligonucleotide also can contain nucleotide analogs, including non-naturally occurring synthetic nucleotides or modified naturally occurring nucleotides.
- the covalent bond linking the nucleotides of a polynucleotide generally is a phosphodiester bond.
- the covalent bond also can be any of numerous other bonds, including a thiodiester bond, a phosphorothioate bond, a peptide-like amide bond or any other bond known to those in the art as useful for linking nucleotides to produce synthetic polynucleotides.
- nucleotide analogs or bonds linking the nucleotides or analogs can be particularly useful where the polynucleotide is to be exposed to an environment that can contain a nucleolytic activity, including, for example, a tissue culture medium or upon administration to a living subject, since the modified polynucleotides can be less susceptible to degradation.
- selective hybridization or selectively hybridize refers to hybridization under moderately stringent or highly stringent conditions such that a nucleotide sequence preferentially associates with a selected nucleotide sequence over unrelated nucleotide sequences to a large enough extent to be useful in identifying the selected nucleotide sequence.
- non-specific hybridization can occur, but is acceptable provided that hybridization to a target nucleotide sequence is sufficiently selective such that it can be distinguished over the non-specific cross- hybridization, for example, at least about 2-fold more selective, generally at least about 3.-fold more selective, usually at least about 5-fold more selective, and particularly at least about 10- fold more selective, as determined, for example, by an amount of labeled oligonucleotide that binds to target nucleic acid molecule as compared to a nucleic acid molecule other than the target molecule, particularly a substantially similar or homologous nucleic acid molecule other than the target nucleic acid molecule.
- Conditions that allow for selective hybridization can be determined empirically, or can be estimated based, for example, on the relative GC: AT content of the hybridizing oligonucleotide and the sequence to which it is to hybridize, the length of the hybridizing oligonucleotide, and the number, if any, of mismatches between the oligonucleotide and sequence to which it is to hybridize.
- An example of progressively higher stringency conditions is as follows: 2 x SSC / 0.1% SDS at about room temperature (hybridization conditions); 0.2 x SSC / 0.1% SDS at about room temperature (low stringency conditions); 0.2 x SSC / 0.1% SDS at about 42°C (moderate stringency conditions); and 0.1 x SSC at about 68°C. (high stringency conditions). Washing can be carried out using only one of these conditions, for example, high stringency conditions, or each of the conditions can be used, for example, for 10-15 minutes each, in the order listed above, repeating any or all of the steps listed. However, as mentioned above, optimal conditions will vary, depending on the particular hybridization reaction involved, and can be determined empirically.
- the colloidal particles can include an antibody probe.
- antibody is used in its broadest sense to include polyclonal and monoclonal antibodies, as well as antigen binding fragments of such antibodies.
- An antibody useful in a method of the invention, or an antigen binding fragment thereof, is characterized, for example, by having specific binding activity for an epitope of an analyte.
- an antibody can be detected using these antibody probe-modified colloidal particles.
- the antibodies which can be detected include naturally occurring antibodies as well as non-naturally occurring antibodies, including, for example, single chain antibodies, chimeric, bifunctional and humanized antibodies, as well as antigen-binding fragments thereof.
- non-naturally occurring antibodies can be constructed using solid phase peptide synthesis, can be produced recombinantly or can be obtained, for example, by screening combinatorial libraries consisting of variable heavy chains and variable light chains.
- the term binds specifically or specific binding activity, when used in reference to an antibody means that an interaction of the antibody and a particular epitope has a dissociation constant of at least about 1 x 10 ⁇ 6 , generally at least about 1 x 1(J 7 , usually at least about 1 x 10 "8 , and particularly at least about 1 x 10 "9 or 1 x lO "10 or less.
- Fab, F(ab')2, Fd and Fv fragments of an antibody that retain specific binding activity for an epitope of an antigen are included within the definition of an antibody.
- the analyte detection methods disclosed herein can be performed, for example, by traditional sandwich assays known in the art. Such assays are described, for instance, in U.S. Patent 5,637,508; 5,639,626; 5,710,006; 6,096,563; 6,544,776; 6,686,208; and 6,670,115, each of which is incorporated herein by reference in its entirety.
- the detection of the analyte in a sample can be performed by contacting a sample containing an analyte with a colloidal particle of the present invention which is modified to include a probe, wherein the probe binds to the analyte; and further contacting the sample with another probe which also binds to the analyte, wherein this second probe allows for the removal of the bound analyte from the sample, through, e.g., immobilization, magnetic separation, and the like.
- the bound colloidal particle then, can be redissolved in pyridine and the fluorescence signal measured, wherein the fluorescence signal is indicative of the presence and/or concentration of the analyte in the sample. This amplification of fluorescence is such that very low levels of analyte can be detected.
- analyte means any molecule or compound.
- An analyte can be in the solid, liquid, gaseous or vapor phase.
- gaseous or vapor phase analyte is meant a molecule or compound that is present, for example, in the headspace of a liquid, in ambient air, in a breath sample, in a gas, or as a contaminant in any of the foregoing. It will be recognized that the physical state of the gas or vapor phase can be changed by pressure, temperature as well as by affecting surface tension of a liquid by, for example, the presence of or addition of salts.
- analyte detect binding of an analyte to a probe.
- the analyte can be comprised of a member of a specific binding pair (sbp) and maybe a ligand, which is monovalent (monoepitopic) or polyvalent (polyepitopic), usually antigenic or haptenic, and is a single compound or plurality of compounds which share at least one common epitopic or determinant site.
- the analyte can be a part of a cell such as bacteria or a cell bearing a blood group antigen such as A, B, D, etc., or an HLA antigen or a microorganism, e.g., bacterium, fungus, protozoan, or virus. In some cases, the analyte is charged.
- a member of a specific binding pair is one of two different molecules, having an area on the surface or in a cavity which specifically binds to and is thereby defined as complementary with a particular spatial and polar organization of the other molecule.
- the members of the specific binding pair are referred to as ligand and receptor (antiligand) or analyte and probe. Therefore, a probe is a molecule that specifically binds an analyte.
- immunological pair such as antigen-antibody
- specific binding pairs such as biotin-avidin, protein-lectin, hormones-hormone receptors, nucleic acid duplexes, IgG-protein A, polynucleotide pairs such as DNA-DNA, DNA-RNA, and the like are not immunological pairs but are included in the invention and the definition of sbp member.
- Specific binding is the specific recognition of one of two different molecules for the other compared to substantially less recognition of other molecules.
- the molecules have areas on their surfaces or in cavities giving rise to specific recognition between the two molecules.
- Exemplary of specific binding are antibody-antigen interactions, enzyme- substrate interactions, polynucleotide hybridization interactions, and so forth.
- Non-specific binding is non-covalent binding between molecules that is relatively independent of specific surface structures. Non-specific binding may result from several factors including hydrophobic interactions between molecules.
- the colloidal particles of the present invention can be used to detect the presence of a particular target analyte, for example, a nucleic acid, oligonucleotide, protein, enzyme, antibody, or antigen.
- the colloidal particles can also be used to screen bioactive agents, such as, for example, drug candidates, for binding, to a particular target or to detect agents like pollutants.
- bioactive agents such as, for example, drug candidates, for binding, to a particular target or to detect agents like pollutants.
- any analyte for which a probe moiety, such as a peptide, protein, oligonucleotide or aptamer, may be designed can be used in combination with the disclosed colloidal particles.
- analytes include poly(amino acids), such as for example, polypeptides and proteins, polysaccharides, hormones, nucleic acids, and combinations thereof.
- poly(amino acids) such as for example, polypeptides and proteins, polysaccharides, hormones, nucleic acids, and combinations thereof.
- combinations include components of bacteria, viruses, prions, cells, chromosomes, genes, mitochondria, nuclei, cell membranes and the like.
- Additional possible analytes include drugs, metabolites, pesticides, pollutants, and the like. Included among drugs of interest are the alkaloids.
- alkaloids include morphine alkaloids, which includes morphine, codeine, heroin, dextromethorphan, their derivatives and metabolites; cocaine alkaloids, which include cocaine and benzyl ecgonine, their derivatives and metabolites; ergot alkaloids, which include the diethylamide of lysergic acid; steroid alkaloids; iminazoyl alkaloids; quinazoline alkaloids; isoquinoline alkaloids; quinoline alkaloids, which include quinine and quinidine; diterpene alkaloids, their derivatives and metabolites.
- analyte further includes polynucleotide analytes such as those polynucleotides defined below. These include, for example, m-RNA, r-RNA, t-RNA, DNA, and DNA-RNA duplexes.
- the term analyte also includes receptors that are polynucleotide binding agents, such as, for example, peptide nucleic acids (PNA), restriction enzymes, activators, repressors, nucleases, polymerases, histones, repair enzymes, chemotherapeutic agents, and the like.
- PNA peptide nucleic acids
- the analyte may be a molecule found directly in a sample such as a body fluid from a host.
- the sample can be examined directly or may be pretreated to render the analyte more readily detectible.
- the analyte of interest may be determined by detecting an agent probative of the analyte of interest such as a specific binding pair member complementary to the analyte of interest, whose presence will be detected only when the analyte of interest is present in a sample.
- the agent probative of the analyte becomes the analyte that is detected in an assay.
- the body fluid can be, for example, urine, blood, plasma, serum, saliva, semen, stool, sputum, cerebral spinal fluid, tears, mucus, and the like.
- probes can be attached to colloidal particles through attachment via surface carboxylate moieties of the colloidal particle.
- colloidal particles may be coupled with probes through biotin-avidin linkages.
- avidin or streptavidin (or an analog thereof) can be covalently attached to the surface of the colloidal particles through one or more available carboxylate moieties a and a biotin-modified probe contacted with the avidin or streptavidin-niodified surface forming a biotin-avidin (or biotin- streptavidin) linkage.
- avidin or streptavidin may be attached in combination with another protein, such as BSA, and optionally be crosslinked.
- Probes having an amine, hydroxyl, or carboxylic acid functional group can be attached through water-soluble carbodiimide coupling reagents, such as EDC (l-ethyl-3 -(3 -dimethyl aminopropyl)carbodiimide), or other coupling agents well known in the art, which couples carboxylic acid functional groups with amine groups, hydroxyl groups, and/or other carboxylic acid functional groups.
- EDC l-ethyl-3 -(3 -dimethyl aminopropyl)carbodiimide
- Nucleotides attached to a variety of functional groups may be commercially obtained (for example, from Molecular Probes, Eugene, Oreg.; Quiagen (Operon), Valencia, Calif.; and IDT (Integrated DNA Technologies), Coralville, Iowa) and incorporated into oligonucleotides or polynucleotides.
- Biotin-modified nucleotides are commercially available (for example, from Pierce Biotechnology, Rockford, 111., or Panomics, Inc. Redwood City, Calif.) and modified nucleotides can be incorporated into nucleic acids during conventional amplification techniques.
- Oligonucleotides may be prepared using commercially available oligonucleotide synthesizers (for example, Applied Biosystems, Foster City, Calif). Additionally, modified nucleotides may be synthesized using known reactions, such as for example, those disclosed in, Nelson, P., Sherman-Gold, R, and Leon, R, "A New and Versatile Reagent for Incorporating Multiple Primary Aliphatic Amines into Synthetic Oligonucleotides," Nucleic Acids Res., 17:7179-7186 (1989) and Connolly, B., Rider, P.
- nucleotide precursors may be purchased containing various reactive groups, - such as biotin, hydroxyl, sulfhydryl, amino, or carboxyl groups.
- colloidal particles may be attached using standard chemistries.
- Oligonucleotides of any desired sequence, with or without reactive groups for colloidal particle attachment may also be purchased from a wide variety of sources (for example, Midland Certified Reagents, Midland, Tex.).
- Probes such as polysaccharides
- colloidal particles for example, through methods disclosed in Aslam, M. and Dent, A., Bioconjugation: Protein Coupling Techniques for the Biomedical Sciences, Grove's Dictionaries, Inc., 229, 254 (1998). Such methods include, but are not limited to, periodate oxidation coupling reactions and bis-succinimide ester coupling reactions.
- colloidal particle-labeled antibodies i.e., antibodies bound to a colloidal particle
- colloidal particle-labeled antibodies are used to detect interaction of the colloidal particle-labeled antibodies with antigens.
- immunoassays can be performed using known methods such as, for example, ELISA assays, Western blotting, or protein arrays, utilizing the colloidal particle-labeled antibody or colloidal particle-labeled secondary antibody, in place of a primary or secondary antibody labeled with an enzyme or a radioactive compound.
- Another group of exemplary methods uses colloidal particle probes to detect a target nucleic acid. Such a method is useful, for example, for detection of infectious agents within a clinical sample, detection of an amplification product derived from genomic DNA or RNA or message RNA, or detection of a gene (cDNA) insert within a clone.
- an oligonucleotide probe is synthesized using methods known in the art. The oligonucleotide probe then is used to functionalize a colloidal particle to produce a colloidal particle-labeled oligonucleotide probe.
- the colloidal particle-labeled oligonucleotide probe is used in a hybridization reaction to detect specific binding of the colloidal particle-labeled oligonucleotide probe to a target polynucleotide.
- the colloidal particle-labeled oligonucleotide probe can be used in a Northern blot or a Southern blot reaction.
- the colloidal particle-labeled oligonucleotide probe can be applied to a reaction mixture that includes the target polynucleotide associated with a solid support, to capture the colloidal particle-labeled oligonucleotide probe.
- the captured colloidal particle-labeled oligonucleotide probe can then be detected using fluorescence spectroscopy, with or without first being released from the solid-support. Detection of the captured colloidal particle-labeled oligonucleotide probe can be amplified by first dissolving the isolated hybridized entity, wherein the monomelic BMSB are released into solution. Because the fluorescence particles used in this method are composed of a huge number of fluorescence molecules (e.g., Zn-BMSB), the approach allows for detection of small amounts of target analyte, down to about 5 aM (10 "18 M).
- a sample includes a wide variety of analytes that can be analyzed using the colloidal particles described herein.
- a sample can be an environmental sample and includes atmospheric air, ambient air, water, sludge, soil, and the like.
- a sample can be a biological sample, including, for example, a subject's breath, saliva, blood, urine, feces, various tissues, and the like.
- colloidal particles described herein Commercial applications for the invention methods employing the colloidal particles described herein include environmental toxicology and remediation, biomedicine, materials quality control, monitoring of food and agricultural products for the presence of ⁇ pathogens, anesthetic detection, automobile oil or radiator fluid monitoring, breath alcohol analyzers, hazardous spill identification, explosives detection, fugitive emission identification, medical diagnostics, fish freshness, detection and classification of bacteria and microorganisms both in vitro and in vivo for biomedical uses and medical diagnostic uses, monitoring heavy industrial manufacturing, ambient air monitoring, worker protection, emissions control, product quality testing, leak detection and identification, oil/gas petrochemical applications, combustible gas detection, H 2 S monitoring, hazardous leak detection and identification, emergency response and law enforcement applications, illegal substance detection and identification, arson investigation, enclosed space surveillance, utility and power applications, emissions monitoring, transformer fault detection, food/beverage/agriculture applications, freshness detection, fruit ripening control, fermentation process monitoring and control applications, flavor composition and identification, product quality and identification, refrigerant and fumigant
- Another application for the sensor-based fluid detection device in engine fluids is an oil/antifreeze monitor, engine diagnostics for air/fuel optimization, diesel fuel quality, volatile organic carbon measurement (VOC), fugitive gases in refineries,, food quality, halitosis, soil and water contaminants, air quality monitoring, fire safety, chemical weapons identification, use by hazardous material teams, explosive detection, breathalyzers, ethylene oxide or anesthetics detectors.
- VOC volatile organic carbon measurement
- Solvents and all other chemicals were obtained from commercial sources and used as received unless otherwise noted. AU deuterated solvents were purchased and used as received from Cambridge Isotopes Laboratories. 1 H and 13 C NMR spectra were obtained using a Varian Mercury 300 MHz or a Varian INOVA 400 MHz FT-NMR spectrometers. Infrared spectra of solid samples were obtained on a Thermo Nicolet Nexus 670 FT-IR spectrometer as KBr pellet. Diffuse reflectance spectra were obtained on a Varian Gary 5000 UV-Vis-NIR spectrophotometer.
- Emission spectra were obtained on a Jobin Yvon SPEX Fluorolog fiuorometer using quartz cells (10 x 4 mm light path).
- Electrospray ionization mass spectrometric (ESI-MS) spectra were obtained on a Micromass Quatro II Triple Quadrupole mass spectrometer, and all peaks are cosnsitent with a natural abundance isotopic distribution patterns. Elemental analyses were obtained from Quantitative Technologies Inc., Whitehouse, NJ.
- Zn-BMSB 2a BSB SIa, synthesized as decribed above, (5 mg, 0.008 mmol) and Zn(OAc) 2 (3 mg, 0.016 mmol) were mixed in DMF (3 mL). The color of the solution changed immediately from yellow to red. Diethyl ether was added to precipitate the product as an orange powder (84% yield). The precipitate product was separated from supernatant and washed with diethyl ether (84% yield).
- IR (KBr pellet, cm 4 ): 1659s, 1609s, 1588s, 1539w, 1506w, 1491m, 1425m, 1383s, 1339m, 1298m, 1223w, 1198w, 1173w, 1151w, 1121m, 1104m, 1061w, 1044w, 1024w, 958m, 898w, 843m, 788m, 748m, 663m, 478w.
- Cu-BMSB 2b 2b was prepared using the same method as for 2a, except Cu(OAb) 2 (H 2 O) was used instead OfZn(OAc) 2 . A brown powder was obtained in 86% yield.
- IR (KBr pellet, cm “1 ): 1653s, 1604s, 1585s, 1539w, 1522w, 1491m, 1427m, 1386s, 1369s, 1340m, 13Q6m, 126Ow, 1225w, 1194w, 1173w, 115Ow, 1123m, 1102m, 106 Iw, 1044w, 1023w, 956m, 898w, 846m, 784m, 748m, 666m, 506w, 481 w.
- X-ray crystal structure determination of 2b A dark tabular crystal was mounted using oil on a glass fiber. Diffraction intensity data were collected with a Bruker SMART- 1000 CCD diffractometer equipped with a graphite-monochromated Mo Ka radiation source. The data collected were processed to produce conventional intensity data by the program SAINT-NT (Bruker). The intensity data were corrected for Lorentz and polarization effects. Absorption corrections were applied using the SADABS empirical method. The structures were solved by direct methods, completed by subsequent difference Fourier syntheses and refined by full matrix least-squares procedures, on F 2 . The disordered methanol was refined with a group anisotropic displacement parameter ⁇ and occupancies adding to fully occupied.
- the remaining non-hydrogen atoms were refined anisotropically. Hydrogen atoms were included in idealized positions, except those on the disordered and partially occupied methanol, and the hydrogen atom on 05 (methanol), but not refined. The DMF was fixed to 1 A occupied. All software and sources of scattering factors are contained in the SHELXTL program package (version 5.10, G. Sheldrick, Bruker- AXS, Madison, WI).
- Ni-BMSB 2c 2c was prepared using the same method as for 2a, except Ni(OAc) 2 -4(H 2 O) was used instead OfZn(OAc) 2 . A red powder was obtained in 82% yield.
- ESI-MS m/z, pyridine/CH 2 Cl 2 ): calcd for [SIa - 4H + + 2Ni 2+ + 2 pyridine + H + J + , 883.1; found, 882.8.
- IR (KBr pellet, cm “1 ): 1655s, 1608s, 1584s, 1545w, 1491m, 1419m, 1387s, 1339m, 1304m, 1263w, 1226w, 1193w, 1173w, 1151w, 1119m, 1104m, 1061w, 1048w, 1026w, 960m, 901 w, 841m, 786m, 749m, 668m, 517w, 479w.
- 2d was. prepared using the same method as for 2a, except BSB SIb was used instead of BSB SIa. An orange powder was obtained in 81% yield.
- the electrospray ionization mass spectra of 3b and 3c exhibit intense peaks associated with the metal-metalloligand repeat units, [2b - 2H + + Cu 2+ + (pyridine),, + H + J + and [2c - 2H + + Ni 2+ + (pyridine),, + H + ] + .
- the NMR spectra of 3b and 3c were not informative because of the paramagnetic nature of these complexes, and the mass spectrum of 3a did not yield a monomer ion.
- the measurement of Zeta potential of these particles reveals that particles are negatively charged (-12 mV), which is a result of the deprotonated carboxylate groups located on their surfaces.
- Ancillary Iigands exchange reactions The 1 H NMR spectra of the methanol- ⁇ and OMSO-d ⁇ suspension of spherical particles 3a with ancillary Iigands L of pyridine and methanol respectively, show the peaks for free pyridine and methanol molecules, which are released from the metal upon replacement with methanol- ⁇ and OMSO-dg, respectively.
- IR (KBr pellet, cm “1 ): 1605s, 1591sh, 1539m, 1506w, 1489w, 1465w, 1448m, 1425w, 1375s, 1341m, 1327m, 1299m, 1217m, 1194w, 1171w, 1148m, 1121m, 1069m, 1042m, 1015w, 955w, 894w, 842m, 787m, 749m, 698m, 663m, 636m, 478w, 419w.
- Cu-BMSB-Cu 3b ESI-MS (m/z, pyridme/CH 2 Cl 2 ): calcd for [SIa - 6H + + 3Cu 2+ + 3 pyridine + H + J + , 1033.0; found, 1032.7, calcd for [SIa - 6H + + 3Cu 2+ + 2 pyridine + H + ] + , 954.0; found, 954.0.
- IR (KBr pellet, cm “1 ): 1602s, 1589sh, 1539m, 1507w, 149Ow, 1466w, 1449m, 1425w, 1369s, 1342m, 1325m, 1262w, 1217m, 119Ow, 1172w, 1148m, 1124m, 1069m, 1043m, 1017w, 955w, 897w, 846m, 783m, 748m, 696m, 671m, 639m, 504w, 479w, 419w.
- Ni-BMSB-Ni 3c ESI-MS (m/z, pyridine/CH 2 Cl 2 ): calcd for [SIa - 6H + + 3Ni 2+ + 4 pyridine + H + ] + , 1097.1; found, 1097.0.
- IR (KBr pellet, cm '1 ): 1597s, 1589sh, 1542m, 1507w, 1497w, 1465w, 1448m, 1429w, 1385s, 1369m, 1343m, 1324m, 1269w, 1217m, 1192w, 1172w, 1149m, 1125m, 1070m, 1042m, 1017w, 951w, 897w, 856m, 786m, 757m, 693m, 639w, 516w, 494w, 419w.
- FIG. 9 shows a schematic of the structures of both the MMP and the colloidal particles.
- Fluorescence Amplification Based Bioassay for DNA The fluorescence amplification based bioassay method was tested with oligonucleotide associated with the anthrax lethal factor (5'-GGA TTA TTG TTA AAT ATT GAT AAG GAT-3') (SEQ. ID. NO: 3) in 0.3 M PBS buffer containing 0.025% Tween 20 as a target over a range of 5 aM (10 "18 ) to 50 fM (10 "15 M).
- a sample solution (50 ⁇ L) with a set of target DNA concentration was added to a 50 ⁇ L of MMP probes functionalized with a single-strand DNA (SEQ.
- SEQ. ID NO: 1 to capture the target DNA, and the solution was shaken on an orbital shaker at 50° C for 15 minutes and at 20°C for 45 minutes.
- the fluorescence particles functionalized with a single-strand DNA (SEQ. ID NO: 2) to form a sandwich structure with the MMP probes that have captured the target DNA (e.g., SEQ. ID NO: 3) were then added to the solution. This solution was vigorously stirred at 20° C for 2 hours.
- the magnetic separator was used to concentrate both unreacted magnetic particles and magenetic particles which captured the target DNA and fluorescence colloidal particles. These particles were vigorously washed six times with 0.3 M PBS buffer containing 0.025% Tween 20 to remove any unreacted fluorescence colloidal particles.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nanotechnology (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
- Investigating Or Analyzing Non-Biological Materials By The Use Of Chemical Means (AREA)
Abstract
Colloidal particles of infinite coordination polymers are disclosed. Also disclosed are methods of synthesizing the colloidal particles and methods of detecting biological and chemical analytes using, the colloidal particles.
Description
CHEMICALLY TAILORABLE NANOPARTICLES REALIZED THROUGH METAL-METALLOLIGAND COORDINATION CHEMISTRY
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims the benefit of U.S. Provisional Application Serial No. 60/685,786, filed May 31, 2005, and U.S. Provisional Application Serial No. 60/777,638, filed February 28, 2006, each of which is incorporated in its entirety by reference.
STATEMENT OF GOVERNMENTAL INTERESTS [0002] This invention was made with government support under National Science Foundation grant Nos. EEC-0118025/003 and CHE-0447674; Office of Naval Research grant No. 00014-06-1-0078; Air Force Office of Scientific Research grant No. F49620-00-1-0283; and Homeland Security Advanced Research Projects Agency grant No. W8IXWH-05-2- 0036. The government has certain rights in this invention.
BACKGROUND
[0003] Micro- and nano-sized particles play important roles in many different areas, including catalysis, optics, biosensing, and data storage. Recent advances in this field have made it possible to control many of the chemical and physical properties of these solid-state materials through control over their size, shape, and composition. (Peng, et al. Nature 404:59 (2000); Horn et al., Angew. Chem. Int. Ed. 40:4331 (2001); and Chen et al. Angew. Ckem. Int. Ed. 44:2589 (2005)). One important goal in this area is an ability to intentionally interconvert different particle compositions and structures through chemistry that occurs throughout the particle structure, in addition to chemistry on its surface. There are two ways to effect such transformations, either through a thermal or photochemically induced shape change (Jin et al., Science 294:1901 (2001)) or by chemical means that transform the particle from one chemical composition to another. (Son et al., Science 306:1009 (2004)) Even though the latter approach, in principle, can provide a straightforward, economic, and potentially powerful way to access new classes of micro- and nanoparticle materials, very few such approaches have been developed, and those that have been realized are quite limited in scope.
[0004] Typically, chemical transformations in the solid state require a high activation energy for the diffusion of small molecules or ions into the solid. Therefore, the reactions are usually slow and involve high temperature and/or pressure. (Feng et al. Ace. Chem. Res .34:239(2001) and Schaak et al., Chem. Mαter.l4:1455(2002)) One exception is that CdSe can be converted to Ag2Se in the context of nano-sized particles at room temperature.
(Son et al., Science 306:1009 (2004)) In contrast, metal-organic coordination polymers are highly porous materials, that often allow small molecules to move freely within such structures. For this reason, they are typically used for gas storage (Yaghiet al. Nature 423:705 (2003) and Zhao et al. Science 306:1012 (2004)) and catalysis. (Seo et al. Nature 404:982 (2000))
[0005] Thus, there remains a need for particles which can be easily assembled, can be modified to provide desired physical and/or chemical properties, and can be used a multitude of applications.
SUMMARY
[0006] Disclosed herein are colloidal particles comprising metal-organic coordination polymers. The colloidal particles are assembled from a coordination of a metal salt and bis- metallo-tridentate Schiff base (BMSB) building blocks. The colloidal particles of the present invention have a formula (I) or (II):
wherein R1 is independently selected from the group consisting of H, hydroxyl, C1-8alkyl, OC1-8 alkyl, Ci-8heteroalkyl, OC1-8heteroalkyl, P(R2)2, aryϊ, heteroaryl; R2 is the same or different and is selected from aryl or heteroaryl; R3 is independently selected from the group consisting of H, hydroxyl, C1-8alkyl, OCi-8 alkyl, C1-8heteroalkyl, OC1-8heteroalkyl, P(R2)2, aryl, heteroaryl; M and M' are independently selected from the group consisting of Zn, Cu, Mn, Pb, Ni, Cd, Co, and Cr; L is null or a ligand selected from the group consisting of pyridine, methanol, acetate, dimethylsulfoxide, dimethylformamide, acetone, water, chloride, fluoride, iodide, bromide, and hydroxide; x is an integer from 0 to 3; n is an integer from 0 to 5; and m is an integer from about 100 to about 10,000. In some embodiments, M and M' are the same metal ion, while in other embodiments, M and M' are different metal ions.
[0007] Also disclosed herein is a method of synthesizing the colloidal particles, wherein a metal salt solution and BMSB are admixed, then a nonpolar solvent is added to the
admixture. Nonlimiting examples of a nonpolar solvent are pentane, diethyl ether, hexane, benzene, xylenes, cyclohexane, and toluene. In some embodiments^ the nonpolar solvent is added rapidly to the mixture of metal salt and BMSB, and the resulting colloidal particles have a diameter of about 100 to less than 1 μm. In other embodiments, the nonpolar solvent is added slowly, and the resulting colloidal particles have a diameter of about 1 μm to about 5 μm.
[0008] Also disclosed herein are methods of using the colloidal particles in biological or chemical detection assays using a sandwich assay, hi one embodiment, a sample containing or suspected of containing an analyte of interest is mixed with (1) a magnetic microparticle (MMP) which is modified with a tag. on its surface that is specific for the analyte and (2) a colloidal particle of the present invention which is modified with a tag on its surface that is specific for the analyte. A sandwich structure of MMP-analyte-colloidal particle results, and is isolated, e.g., using a magnet. The sandwich structure then is dissolved in pyridine, and a fluorescence is measured. The fluorescence is correlated to the presence or concentration of the analyte of interest. In some embodiments, the colloidal particles comprise Zn.
BRIEF DESCRIPTION OF THE DRAWINGS
[0009] FIG. 1 shows a schematic of the preparation of colloidal particles of the invention from metal salts and bis-metallo-tridentate Schiff base (BMSB) building blocks;
[0010] FIG. 2 shows images, of colloidal particles prepared by the disclosed methods and analyzed by (a) optical microscopy, (b) and (c) fluorescence microscopy, and (d) scanning electron microscopy (SEM) where the inset in (d) is a high-resolution zoom-in image of the colloidal particles;
[0011] FIG. 3 shows SEM and optical microscopy images of example micro- and nanoparticles formed through the methods disclosed herein and the proposed mechanism of formation, where (a)-(c) are SEM images monitoring the growth of Zn-BMSB-Zn colloidal particles, (a) is an early intermediate cluster formed by aggregation of small particles, (b) is an intermediate at a later stage, showing surface annealing, (c).is a fully formed spherical particle, (d) is a dark-field optical microscopy image of cluster aggregates (bottom) and a fully formed particle (top), (e) is a schematic representation of the proposed cluster-fusion growth mechanism, (f) is an image of spherical particles of Zn-BMSB-Zn with an average diameter of 190 ± 60 nm (s.d., n= 50) as determined by SEM and 176 ran as determined by dynamic light scattering (DLS); (g) is an image of spherical particles of Zn-BMSB-Zn with
an average diameter of 780 ± 230 nm (s.d., n= 50) as determined by SEM and 575 nm as determine by DLS;
[0012] FIG. 4 shows emission spectra (excitation wavelength of 420 nm) of Zn-BMSB-Zn particles where the ancillary ligands have been systematically changed to dimethyl sulfoxide (DMSO), pyridine, dimethylformamide, acetone, methanol, or water;
[0013] FIG. 5 shows a schematic of selective cation exchange of disclosed colloidal particles, where mixture of a colloidal particle and a metal salt (M") allows for the exchange of the M' ion of the colloidal particle to the M" ion, while the M ion remains unaffected;
[0014] FIG. 6 shows the chemical transformation of Zn-BMSB-Zn colloidal particles to Cu-BMSB-Zn particles via cation exchange, where (a) shows both the optical microscopy (OM, top) and fluorescence microscopy (FM, bottom) images of the mixture at time 0, (b) is at time 1 minute, (c) time 5 minutes, and (d) at time 60 minutes, (e) is a photograph of Zn- BMSB-Zn (right) and Cu-BMSB-Zn (left), and (f) is an emission spectra obtained by exciting at 420 nm;
[0015] FIG. 7 shows SEM images of (a) Zn-BMSB-Zn and (b) Cu-BMSB-Zn, where the scale bars indicate 5 μm;
[0016] FIG. 8 shows OM and FM (inset) images of (a) Zn-BMSB-Zn, (b) Cu-BMSB-Zn, (c) Mn-BMSB-Zn, and (d) Pb-BMSB-Zn, and (e) and (f) are photographs of, from left to right, Zn-BMSB-Zn, Cu-BMSB-Zn, Mn-BMSB-Zn, and Pb-BMSB-Zn, where (f) in with UV-irradation, indicating that only Zn-BMSB-Zn is fluorescent;
[0017] FIG. 9 shows a schematic of an analyte detection method using the colloidal- particles disclosed herein where a capture DNA-modified magnetic probe is mixed with a target DNA and a fluorescent colloidal particle further modified with a capture DNA to form a "sandwich" of the magnetic probe-target DNA-colloidal particle (step 1) and then isolated using a magnetic field (step 2), and dissolved with pyridine to create an amplified fluorescence signal (step 3); and
[0018] FIG. 10 shows (a) fluorescence spectroscopy of solution of colloidal particles dissolved in pyridine as a function of target DNA concentration in PBS buffer, and (b) shows fluorescence intensity of the particles quantified by integration of the area of the spectra from 580 to 615 nm for target DNA concentrations from 5 aM to 50 fM.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0019] Disclosed herein are colloidal particles of polymerized metal-ligand networks made by coordination-chemistry-induced assembly of metal ions and carboxylate functionalized bis-metallo-tridentate Schiff base (BMSB) building blocks (FIG. 1). The colloidal particles are formed by the polymerization of the BMSB and metal, ions, and the size of the colloidal particles can be controlled by the manner in which the BMSB and metal ions are mixed together.
[0020] Colloidal particles of the present invention have a formula (I) or (II):
wherein R1 is independently selected from the group consisting of H, hydroxy!, C1-8alkyl, C1-8 alkoxy, C1-8heteroalkyl, OC1-8heteroalkyl, P(R2)2, aryl, heteroaryl; R2 is the same or different and is selected from aryl or heteroaryl; R3 is independently selected from the group consisting of H, hydroxyl, C1-8alkyl, OC1-8 alkyl, C1-8heteroalkyl, OC1-8heteroalkyl, P(R2)2, aryl, heteroaryl; M and M' are independently selected from the group consisting of Zn, Cu, Mn, Pb, Ni, Cd, Co, and Cr; L is null or a ligand selected from the group consisting of pyridine, methanol, acetate, dimethylsulfoxide, dimethylformamide, acetone, water, chloride, fluoride, iodide, bromide, and hydroxide; x is an integer from 0 to 3; n is an integer from 0 to 5; and m is an integer from about 100 to about 10,000. In some embodiments, M and M' are the same metal ion, while in other embodiments, M and M' are different metal ions.
[0021} As used herein, the term "alkyl" includes straight chained and branched hydrocarbon groups containing the indicated number of carbon atoms, such as methyl, ethyl, and straight chain and branched propyl and butyl groups. The hydrocarbon group can contain up to 8 carbon atoms. The term "alkyl" also encompasses alkyl groups which are optionally substituted with, e.g., one or more halogen atoms, one or more hydroxyl groups, or one or more thiol groups. Also encompassed by the term "alkyl" are cycloalkyl groups. "Cycloalkyl" is defined as a cyclic C3-C8 hydrocarbon group, e.g., cyclopropyl, cyclobutyl,
cyclohexyl, and cyclopentyl. "Heteroalkyl" and "heterocycloalkyl" are defined similar to alkyl and cycloalkyl, except at least one heteroatom is present in the structure. Suitable heteroatoms include N, S, and O.
[0022] The term "halo" or "halogen" is defined herein to include fluorine, bromine, chlorine, and iodine.
[0023] The term "aryl," alone or in combination, is defined herein as a monocyclic or polycyclic aromatic group, preferably a monocyclic or bicyclic aromatic group, e.g., phenyl or naphthyl. Unless otherwise indicated, an "aryl" group can be unsubstituted or substituted, for example, with one or more, and in particular one tα three, halo, alkyl, hydroxy, C(=O)OR, hydroxyalkyl, alkoxy, alkoxyalkyl, halαalkyl, haloalkoxy, cyano, nitro, amino, alkylamino, acylamino, alkylthio, alkylsulfinyl, and alkylsulfonyl. Exemplary aryl groups include phenyl, naphthyl, tetrahydronaphthyl, 2-chlorophenyl, 3-chloropheny.l, 4-chlorophenyl, 2- methylphenyl, 4-methoxyphenyl, 3-trifluoromethylphenyl, 4-nitrophenyl, and the like. The terms "arylC1-3 alkyl" and "heteroarylC1-3alkyl" are defined as an aryl or heteroaryl group having a C1-3alkyl substituent.
[0024] The term "heteroaryl" is defined herein as a monocyclic or bicyclic ring system containing one or two aromatic rings and containing at least one nitrogen, oxygen, or sulfur atom in an aromatic ring, and which can be unsubstituted or substituted, for example, with one or more, and in particular one to three, substituents, like halo, alkyl, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, haloalkyl, nitro, amino, alkylamino, acylamino, alkylthio, alkylsulfinyl, and alkylsulfonyl. Examples of heteroaryl groups include thienyl, furyl, pyridyl, oxazolyl, quinolyl, isoquinolyl, indolyl, triazolyl, isothiazolyl, isoxazolyl, imidizolyl, benzothiazolyl, pyrazinyl, pyrimidinyl, thiazolyl, and thiadiazolyl.
[0025] The term "hydroxy" is defined as -OH.
[0026] The term "alkoxy" is defined as -OR, wherein R is alkyl.
[0027] Colloidal particles of the present invention have a diameter of about 100 nm to about 5 μm, which is dependent upon the manner in which the colloidal particles are prepared. When the colloidal particles are formed through the fast addition of a nonpolar solvent (such as, e.g., diethyl ether or pentane), the result is smaller diameter colloidal particles, while the slow addition of the nonpolar solvent results in larger diameter colloidal particles.
[0028] BMSB molecules can be prepared through known chemical techniques. One such technique is outlined in the following scheme for the formation of a specific, nonlimiting BMSB.
BMSB
[0029] Different BMSBs can be prepared by altering the starting di-aldehyde, aromatic amine, and/or metal salt. The BMSB is then used to prepare the colloidal particles of the present invention. The BMSB building blocks are important components of the strategy for making the colloidal particles disclosed herein. They are readily polymerizable through their carboxylate groups and allow manipulation of the chemical and physical properties of the resulting colloidal particles in a systematic manner through choice of BMSB ligand, type of metallation, and ancillary ligands. The BMSB is mixed with a metal* salt (such as, e.g., M' (OAc)2) in a pyridine solution. The metal of the BMSB may be the same or different from the metal salt used. The colloidal particles are prepared by the addition, either fast (to form smaller diameter colloidal particles) or slow (to form larger diameter colloidal particles), of a nonpolar solvent. The nonpolar solvent, typically pentane or diethyl ether, affects the solubility of the forming colloidal particle. The fast addition of the nonpolar solvent causes the forming colloidal particle to precipitate out of solution more quickly, and the resulting colloidal particles are therefore smaller in diameter. Slow addition of the nonpolar solvent, however, allows for the colloidal particles to grow in solution for a longer period of time before precipitating out of solution, and, therefore, have larger diameters than those produced from the fast addition of the nonpolar solvent.
[0030] The nonpolar solvent used also effects the size of the resulting colloidal particles. Diethyl ether typically provides smaller diameter colloidal particles, whereas pentane
provides larger diameter colloidal particles under the same conditions. For example, the fast addition of diethyl ether results in colloidal particles having a diameter of about 190 ± 60 rnn, while fast addition of pentane results in colloidal particles having a diameter of about 780 ± 230 nm. Slow addition of diethyl ether results in colloidal particles having a diameter of about 1.60 ± 0.47 μm, and slow addition of pentane results in colloidal particles having a diameter of about 5 μm. Therefore, colloidal particle diameter can be controlled through the appropriate choice of nonpolar solvent and rate of addition of the nonpolar solvent to the mixture of BMSB and metal salt. The polarity of the solvent affects the solubility of the resulting colloidal particles and, therefore, their average size.
[0031] When pentane is used as an initiation solvent instead of diethyl ether, larger spherical microp articles (5 ± 3 μm) are formed (FIG. 2). The growth of the particles under this set of conditions can be observed by taking aliquots at various stages and characterizing the particles by SEM and OM. This set of experiments also provides some mechanistic insight into the particle growth process. Two kinds of intermediate particles, were observed, i.e., clusters formed by aggregation of small particles and a fused version of these clusters. At an early stage of the reaction, clusters of smaller particles are observable (FIG. 2 A and 2D). These structures slowly anneal into single particles having smoother surfaces (FIG. 2B) and ultimately form uniform spherical particles (FIG. 2C and FIG. 2D). Based upon these observations, the proposed mechanism of the formation of the structures is via a two step cluster-fusion growth process (FIG. 2E). The first step is aggregation of several small particles to form large cluster particles. The second step is intraparticle fusion, resulting in large uniform spherical particles. This can occur because of the reversible nature of the metal coordination chemistry, which allows the system to anneal into a smooth particle. The cluster fusion step can involve a plurality of particles or only a few, depending upon conditions, and the ultimate size of the large spherical particles depends upon the number of smaller particles involved in the fusion process.
[0032] The phrase "rapid addition," or interchangeably "fast addition," means herein that the nonpolar solvent is added to the mixture at a rate of at least 1 mL/sec, preferably at least 3 mL/sec, and most preferably at least 5 mL/sec. The phrase "slow addition" means herein that the nonpolar solvent is added to the mixture at a rate of less than 1 mL/sec, preferably less than 1 mL/min, and most preferably, less than 1 mL/hour.
[0033] The term "nonpolar solvent" as used herein means a solvent which is immiscible or only slightly miscible in pyridine. One means of determining whether a solvent is suitable is by its solubility parameter. Solvents with solubility parameters (δ) of less than 19.0 can be
used in the methods disclosed herein, more preferably less than 18.0, and most preferably less than 16.0. Pentane has a solubility parameter of 14.4, diethyl ether has a solubility parameter of 15.4, and toluene a solubility parameter of 18.3. Solubility parameters can be found in any chemistry handbook, such as, e.g., Barton, Handbook of Solubility Parameters, CRC Press (1983). Other examples of nonpolar solvents include benzene, xylenes, hexanes, cyclohexane, amyl acetate, and the like.
[0034] The physical properties of the colloidal particles can be affected both by the manner in which they are synthesized, as. discussed above, but also by the ancillary ligand, L, of the colloidal particle. The ancillary ligand of the colloidal particles can be changed by mixing the colloidal particle with various solvents. For example, a red toluene suspension of colloidal particles 3a (FIG. 1), (M and M' are Zn, L is pyridine, and the BMSB is a compound of formula (I), where R1 is null) turns yellow when methanol is added. This color change is attributable to the replacement of the pyridine ligand on the Zn metal centers with methanol. The solvent can be removed from this complex and the resulting powder redispersed in toluene having 10% dimethylsulfoxide (DMSO). The yellow solution turns red due to the formation of a zinc-DMSO adduct. The emission spectra of colloidal particles having Zn metal centers and various ancillary ligands is shown in FIG. 4, where the ancillary ligand is DMSO, DMF, acetone, methanol, pyridine, or water. The ancillary ligand can be easily altered by simple addition of the appropriate small molecule, and is completely reversible, with the exception of pyridine which dissolves the colloidal particle into its BMSB and metal salt components.
[0035] In a typical experiment, a precursor pyridine solution consisting of a mixture of the appropriate metal acetate salt (e.g., M'(OAc)2, where M' = Zn, Cu, or Ni and OAc = acetate) and BMSB 2 is prepared (FIG. 1). Addition of an initiation solvent such as diethyl ether or pentane results in the spontaneous formation of spherical inorganic polymer particles 3 (FIG. 1). These particles form via coordination of the carboxylate groups on the BMSB precursor with the metal ions supplied by the acetate salt, and the polymerization process is completely reversible as evidenced by the formation of the starting materials upon addition of excess pyridine. Spherical microscale colloidal particles are formed, instead of a macroscopic polymeric material of other reported organometallic polymerizations, due to the slow diffusion of a nonpolar solvent in the pyridine solution of the BMSB and metal salt at room temperature. The addition of diethyl ether or pentane to the polar (e.g., pyridine) precursor solution results in precipitation due to the low solubility of the particles in nonpolar media.
The resulting particles are stable in organic solvents (toluene, methanol, DMF and dimethyl sulfoxide (DMSO)), water, and in the dried state.
[0036] Optical microscopy (OM, FIG. IA), fluorescence microscopy (FM, FIG. 1, B and C), and scanning electron microscopy (SEM, FIG. ID) images of example compositions show the spherical particles with an average diameter of 1.6 ± 1.2 μm. The chemical composition of the particles was determined by energy dispersive X-ray spectroscopy (EDX) and elemental analysis. Control experiments with a BMSB which does not contain a free carboxylate group (2d in FIG. 1) show that the coordination polymer and therefore colloidal particles as disclosed herein will not form in the absence of the carboxylate groups. In addition to the aforementioned control experiments, Fourier transform IR spectroscopy, 1H and 13C NMR spectroscopy, and electrospray ionization mass spectrometry are all consistent with the proposed mode of polymerization. Featureless powder X-ray diffraction data for these particles show that they are amorphous and not crystalline materials.
[0037] Colloidal particles of the present invention can be prepared with a variety of different metals, including Zn, Cu^ Ni, Pd, and Mn, by the choice of starting metal salt and starting BMSB. Spherical nanoparticles of Cu-BMSB-Cu 3b (FIG. 1) synthesized by fast addition of pentane into a precursor solution having Cu-BMSB 2b and Cu(OAc)2-(H2O) Ib in pyridine, have diameters similar to Zn-BMSB-Zn particles prepared via analogous procedures. Slow diffusion of pentane into a precursor solution containing 2b and Ib yields particles that are on average significantly larger than the particles formed from the fast addition method. Similarly, the reaction between Ni-BMSB 2c and Ni(OAc)2-4(H2O) Ic gives spherical particles Ni-BMSB-Ni 3c. hi contrast to 3a, particle compositions of 3b and 3c are not fluorescent because they are not made of fluorescent BMSB building blocks.
[0038] The synthetic methods disclosed herein provide dispersible micro- and nano-scale particles having highly tailorable physical and chemical properties, which can be controlled through choice of polymerizing metal ion, such as Zn(II), Cu(II), or Ni(II), BMSB, and ancillary ligands. Because certain BMSB building blocks can be prepared in enantiopure form (such as, e.g., those based upon a bi-naphthyl ring system) and are important compounds in homogeneous catalysis, this new class of material has great potential in asymmetric catalysis and chiral separations.
[0039] One can also transform the particles prepared as described above into new compositions through selective cation exchange reactions without significantly affecting the size or morphology of the particle. The approach utilizes two different types of ions, ones
coordinated to the tridentate pockets of the BMSB ligands and ones that link the BMSB ligands thorough the carboxylate groups to form the polymers. When Zn(II) is used as the metal ion, it can be readily displaced from the BMSB tridentate pockets, but not from the carboxylate sites with a variety of metal ions (FIG. 5).
[0040] In a typical reaction, a mixture of Zn-BMSB-Zn microparticles (3a, FIG. 1) (average diameter ~ 1.6 μm) and Cu(OAc)2-H2O in methanol was prepared under ambient conditions. The mixture contains Cu(II) ions in a slight excess to ensure the replacement of all the Zn(II) ions coordinated to the tridentate Schiff base moieties within the particles. Zn- BMSB building blocks are highly fluorescent, as are Zn-BMSB-Zn particles, however, the product resulting from cation exchange, Cu-BMSB-Zn is not. Therefore, one can easily monitor particle transformation by optical microscopy (OM) and fluorescence microscopy (FM, FIG. 6 A -6D, compare the OM and FM images). Within five minutes, the majority of the fluorescent Zn-BMSB-Zn particles had been transformed into the Cu-BMSB-Zn particles (FIG. 6C), and by 60 minutes the reaction was complete (FIG. 6D). This transformation was followed by fluorescence or by the naked eye as evidenced by a concomitant color change from orange (Zn-BMSB-Zn) to brown (Cu-BMSB-Zn).
[0041] In addition to these optical property changes, energy dispersive X-ray (EDX) spectra, ICP analyses , and emission spectra measured before and after the cation- exchange reaction were consistent with the formation of the Cu-BMSB-Zn product. The emission spectrum of the resulting particles reveals complete disappearance of fluorescence indicating full exchange of two equivalents of Cu(II) for the two Zn(II) ions contained within the Zn- BMSB building blocks. A separate study of the Zn-BMSB monomer shows that one must remove both Zn ions within the Zn-BMSB to quench the fluorescence from this system. In addition, an EDX spectrum of the Cu-BMSB-Zn particles measured after the cation exchange shows the expected Cu signal in addition to Zn. Finally, ICP analysis data are consistent with a change in the number of metal ions within the particles from three to one Zn(II) ions and from zero to two Cu(II) ions per repeating unit.
[0042] Scanning electron microscopy (SEM) images of initial and cation-exchanged particles show that the size and shape of the particles are preserved after the reaction. From these data, it is concluded that the Cu(II) ions exchange only with the Zn(II) coordinated to the tridentate Schiff base (i.e., the M metal of formulae (I) or (H)) and not the Zn(II) ions forming the interconnecting nodes (i.e, the M' metal of formulae (I) or (IT)). When excess Cu(II) ions are used in the exchange reaction, the reaction occurs at a faster rate, but results in the same product, Cu-BMSB-Zn. Under the conditions studied, there is no evidence for the
formation of the Cu-BMSB-Cu product, which is a reflection of the difference in binding strength of the two coordination sites.
[0043] The cation exchange reaction rate is size dependent. Particles of about 200 nm undergo Cu(II) exchange reaction in a few minutes as compared to the hour required to effect it with the micron-scale particles. Again, FM and OM images clearly show the transformation with a minimal change in particle size; the average particle sizes measured before (212 nm) and after the cation exchange reaction (215 nm) by dynamic light scattering (DLS) are nearly identical (FIG. 8A vs. FIG. 8B).
[0044] The utility of this method was also assessed for producing additional particle compositions with other metal ions such as Mn(II) and Pd(II). A mixture of Zn-BMSB-Zn nanoparticles and Mn(OAc)2 or Pd(OAc)2 in methanol was prepared under ambient conditions. Ih contrast to the process involving Cu(II) exchange, excess Mn(II) or Pd(II) (e.g., greater than 20 equivalents) was necessary in order to observe significant conversion as measured by fluorescence. The transformations can be monitored by florescence or with the naked eye. In addition, the resulting nanoparticles, like their Cu(II) counterparts, were characterized by EDX, DLS, and emission spectroscopy. Other cation exchanges are contemplated. Any metal salt can be used to exchange with the metal M of formulae (I) or (II). Mn(II), Pb(II), Ni(II), Co(II) and Cu(II) are examples of such suitable metal ions, but metal salts of other metals, or of the same metals but alternative oxidation states (such as, e.g., Mn(IV)) are also contemplated. The associated anion of the metal salt is preferably one which is not strongly coordinated to the metal center and can be replaced by alternate coordinating groups, such as, e.g., Schiff bases of the BMSB ligand moieties. Such anions include acetate, trifluoroacetate, halide, nitrate, perchlorate, phosphate, sulfate, triflate, and the like.
[0045] Selective cation exchange within the context of nano- and microparticles.made from infinite coordination polymers can be used to transform one particle composition into several new ones in a very efficient process. The fast rates of these processes, which derive from the porosity of the structures and the labile nature of the Zn-coordination interactions is unexpected, especially when compared to their solid-state counterparts, but extremely useful because it provides a way of creating one precursor set of particles that can be deliberately and controllably transformed into a new stet of compositions with properties that will derive from the metallated BMSB building blocks.
[0046] The colloidal particles disclosed herein can be used as catalysts or as phase transfer agents. The BMSB-metal moiety is a well-known catalytic center, and the colloidal particles can be used as catalysts in the same manner as a typical Schiff base-metal complex can be used. See, for instance, Desimoni et al, Chem. Rev., 103(8): 3119 (2003) and McManus, et al., Chem. i?ev.,104(9): 4151 (2004), each of which is incorporated herein in its entirety.
[0047] The colloidal particles disclosed herein can be used in biological and chemical detection of analytes. Because the colloidal particles are composed of hundred or thousands of fluorescent monomers (such as, e.g., colloidal particles of Zn-BMSB-Zn), minute quantities of an analyte of interest can be detected. The fluorescence of the colloidal particle is amplified by the dissolution of the colloidal particle into its monomelic components. Concentrations as low as about 50 aM (10"18 M) of analyte are detectable using the colloidal particles disclosed herein. (FIG. 10)
[0048] The colloidal particles disclosed herein can be used in "sandwich" type assays. Such assays include, but are not limited to, ELISA, immunoassays using antibody-antigen- antibody interactions, magnetic microparticle (MMP) sandwich assays, and the like, wherein one component of the sandwich assay is modified to incorporate a colloidal particle as disclosed herein.
[0049] For use in the detection of analytes a probe can be attached to the colloidal particle. In certain embodiments, exemplary probes are antibodies, antigens, polynucleotides, oligonucleotides, receptors, ligands, and the like. The term polynucleotide is used broadly herein to mean a sequence of deoxyribonucleotides or ribonucleotides that are linked together by a phosphodiester bond. For convenience, the term oligonucleotide is used herein to refer to a polynucleotide that is used as a primer or a probe. Generally, an oligonucleotide useful as a probe or primer that selectively hybridizes to a selected nucleotide sequence is at least about 10 nucleotides in length, usually at least about 15 nucleotides in length, and for example between about 15 and about 50 nucleotides in length. Polynucleotide probes are particularly useful for detecting complementary polynucleotides in a biological sample.
[0050] A polynucleotide can be RNA or can be DNA, which can be a gene or a portion thereof, a cDNA, a synthetic polydeoxyribonucleic acid sequence, or the like, and can be single stranded or double stranded, as well as a DNA/RNA hybrid. In various embodiments, a polynucleotide, including an oligonucleotide (e.g., a probe or a primer) can contain nucleoside or nucleotide analogs, or a backbone bond other than a phosphodiester bond. In general, the nucleotides comprising a polynucleotide are naturally occurring
deoxyribonucleotides, such as adenine, cytosine, guanine or thymine linked to T- deoxyribose, or ribonucleotides such as adenine, cytosine, guanine or uracil linked to ribose. However, a polynucleotide or oligonucleotide also can contain nucleotide analogs, including non-naturally occurring synthetic nucleotides or modified naturally occurring nucleotides.
[0051] The covalent bond linking the nucleotides of a polynucleotide generally is a phosphodiester bond. However, the covalent bond also can be any of numerous other bonds, including a thiodiester bond, a phosphorothioate bond, a peptide-like amide bond or any other bond known to those in the art as useful for linking nucleotides to produce synthetic polynucleotides. The incorporation of non-naturally occurring nucleotide analogs or bonds linking the nucleotides or analogs can be particularly useful where the polynucleotide is to be exposed to an environment that can contain a nucleolytic activity, including, for example, a tissue culture medium or upon administration to a living subject, since the modified polynucleotides can be less susceptible to degradation.
[0052] As used herein, the term selective hybridization or selectively hybridize, refers to hybridization under moderately stringent or highly stringent conditions such that a nucleotide sequence preferentially associates with a selected nucleotide sequence over unrelated nucleotide sequences to a large enough extent to be useful in identifying the selected nucleotide sequence. It will be recognized that some amount of non-specific hybridization can occur, but is acceptable provided that hybridization to a target nucleotide sequence is sufficiently selective such that it can be distinguished over the non-specific cross- hybridization, for example, at least about 2-fold more selective, generally at least about 3.-fold more selective, usually at least about 5-fold more selective, and particularly at least about 10- fold more selective, as determined, for example, by an amount of labeled oligonucleotide that binds to target nucleic acid molecule as compared to a nucleic acid molecule other than the target molecule, particularly a substantially similar or homologous nucleic acid molecule other than the target nucleic acid molecule. Conditions that allow for selective hybridization can be determined empirically, or can be estimated based, for example, on the relative GC: AT content of the hybridizing oligonucleotide and the sequence to which it is to hybridize, the length of the hybridizing oligonucleotide, and the number, if any, of mismatches between the oligonucleotide and sequence to which it is to hybridize.
[0053] An example of progressively higher stringency conditions is as follows: 2 x SSC / 0.1% SDS at about room temperature (hybridization conditions); 0.2 x SSC / 0.1% SDS at about room temperature (low stringency conditions); 0.2 x SSC / 0.1% SDS at about 42°C (moderate stringency conditions); and 0.1 x SSC at about 68°C. (high stringency conditions).
Washing can be carried out using only one of these conditions, for example, high stringency conditions, or each of the conditions can be used, for example, for 10-15 minutes each, in the order listed above, repeating any or all of the steps listed. However, as mentioned above, optimal conditions will vary, depending on the particular hybridization reaction involved, and can be determined empirically.
[0054] In some embodiments, the colloidal particles can include an antibody probe. As used herein, the term antibody is used in its broadest sense to include polyclonal and monoclonal antibodies, as well as antigen binding fragments of such antibodies. An antibody useful in a method of the invention, or an antigen binding fragment thereof, is characterized, for example, by having specific binding activity for an epitope of an analyte.
[0055] An antibody can be detected using these antibody probe-modified colloidal particles. The antibodies which can be detected include naturally occurring antibodies as well as non-naturally occurring antibodies, including, for example, single chain antibodies, chimeric, bifunctional and humanized antibodies, as well as antigen-binding fragments thereof. Such non-naturally occurring antibodies can be constructed using solid phase peptide synthesis, can be produced recombinantly or can be obtained, for example, by screening combinatorial libraries consisting of variable heavy chains and variable light chains. These and other methods of making, for example, chimeric, humanized, CDR- grafted, single chain, and bifunctional antibodies are well known to those skilled in the art.
[0056] The term binds specifically or specific binding activity, when used in reference to an antibody means that an interaction of the antibody and a particular epitope has a dissociation constant of at least about 1 x 10~6, generally at least about 1 x 1(J7, usually at least about 1 x 10"8, and particularly at least about 1 x 10"9 or 1 x lO"10 or less. As such, Fab, F(ab')2, Fd and Fv fragments of an antibody that retain specific binding activity for an epitope of an antigen, are included within the definition of an antibody.
[0057] The analyte detection methods disclosed herein can be performed, for example, by traditional sandwich assays known in the art. Such assays are described, for instance, in U.S. Patent 5,637,508; 5,639,626; 5,710,006; 6,096,563; 6,544,776; 6,686,208; and 6,670,115, each of which is incorporated herein by reference in its entirety. The detection of the analyte in a sample can be performed by contacting a sample containing an analyte with a colloidal particle of the present invention which is modified to include a probe, wherein the probe binds to the analyte; and further contacting the sample with another probe which also binds to the analyte, wherein this second probe allows for the removal of the bound analyte from the
sample, through, e.g., immobilization, magnetic separation, and the like. The bound colloidal particle, then, can be redissolved in pyridine and the fluorescence signal measured, wherein the fluorescence signal is indicative of the presence and/or concentration of the analyte in the sample. This amplification of fluorescence is such that very low levels of analyte can be detected.
[0058] The term "analyte " means any molecule or compound. An analyte can be in the solid, liquid, gaseous or vapor phase. By gaseous or vapor phase analyte is meant a molecule or compound that is present, for example, in the headspace of a liquid, in ambient air, in a breath sample, in a gas, or as a contaminant in any of the foregoing. It will be recognized that the physical state of the gas or vapor phase can be changed by pressure, temperature as well as by affecting surface tension of a liquid by, for example, the presence of or addition of salts.
[0059] As indicated above, methods of the present invention, in certain aspects, detect binding of an analyte to a probe. The analyte can be comprised of a member of a specific binding pair (sbp) and maybe a ligand, which is monovalent (monoepitopic) or polyvalent (polyepitopic), usually antigenic or haptenic, and is a single compound or plurality of compounds which share at least one common epitopic or determinant site. The analyte can be a part of a cell such as bacteria or a cell bearing a blood group antigen such as A, B, D, etc., or an HLA antigen or a microorganism, e.g., bacterium, fungus, protozoan, or virus. In some cases, the analyte is charged.
[0060] A member of a specific binding pair (sbp member) is one of two different molecules, having an area on the surface or in a cavity which specifically binds to and is thereby defined as complementary with a particular spatial and polar organization of the other molecule. The members of the specific binding pair are referred to as ligand and receptor (antiligand) or analyte and probe. Therefore, a probe is a molecule that specifically binds an analyte. These will usually be members of an immunological pair such as antigen-antibody, although other specific binding pairs such as biotin-avidin, protein-lectin, hormones-hormone receptors, nucleic acid duplexes, IgG-protein A, polynucleotide pairs such as DNA-DNA, DNA-RNA, and the like are not immunological pairs but are included in the invention and the definition of sbp member.
[0061] Specific binding is the specific recognition of one of two different molecules for the other compared to substantially less recognition of other molecules. Generally, the molecules have areas on their surfaces or in cavities giving rise to specific recognition between the two molecules. Exemplary of specific binding are antibody-antigen interactions, enzyme-
substrate interactions, polynucleotide hybridization interactions, and so forth. Non-specific binding is non-covalent binding between molecules that is relatively independent of specific surface structures. Non-specific binding may result from several factors including hydrophobic interactions between molecules.
[0062] The colloidal particles of the present invention can be used to detect the presence of a particular target analyte, for example, a nucleic acid, oligonucleotide, protein, enzyme, antibody, or antigen. The colloidal particles can also be used to screen bioactive agents, such as, for example, drug candidates, for binding, to a particular target or to detect agents like pollutants. As discussed above, any analyte for which a probe moiety, such as a peptide, protein, oligonucleotide or aptamer, may be designed can be used in combination with the disclosed colloidal particles.
[0063] In particular, analytes include poly(amino acids), such as for example, polypeptides and proteins, polysaccharides, hormones, nucleic acids, and combinations thereof. Such combinations include components of bacteria, viruses, prions, cells, chromosomes, genes, mitochondria, nuclei, cell membranes and the like. Additional possible analytes include drugs, metabolites, pesticides, pollutants, and the like. Included among drugs of interest are the alkaloids. Among the alkaloids are morphine alkaloids, which includes morphine, codeine, heroin, dextromethorphan, their derivatives and metabolites; cocaine alkaloids, which include cocaine and benzyl ecgonine, their derivatives and metabolites; ergot alkaloids, which include the diethylamide of lysergic acid; steroid alkaloids; iminazoyl alkaloids; quinazoline alkaloids; isoquinoline alkaloids; quinoline alkaloids, which include quinine and quinidine; diterpene alkaloids, their derivatives and metabolites.
[0064] The term analyte further includes polynucleotide analytes such as those polynucleotides defined below. These include, for example, m-RNA, r-RNA, t-RNA, DNA, and DNA-RNA duplexes. The term analyte also includes receptors that are polynucleotide binding agents, such as, for example, peptide nucleic acids (PNA), restriction enzymes, activators, repressors, nucleases, polymerases, histones, repair enzymes, chemotherapeutic agents, and the like.
[0065] The analyte may be a molecule found directly in a sample such as a body fluid from a host. The sample can be examined directly or may be pretreated to render the analyte more readily detectible. Furthermore, the analyte of interest may be determined by detecting an agent probative of the analyte of interest such as a specific binding pair member complementary to the analyte of interest, whose presence will be detected only when the
analyte of interest is present in a sample. Thus, the agent probative of the analyte becomes the analyte that is detected in an assay. The body fluid can be, for example, urine, blood, plasma, serum, saliva, semen, stool, sputum, cerebral spinal fluid, tears, mucus, and the like.
[0066] In general, probes can be attached to colloidal particles through attachment via surface carboxylate moieties of the colloidal particle. Alternatively, colloidal particles may be coupled with probes through biotin-avidin linkages. For example, avidin or streptavidin (or an analog thereof) can be covalently attached to the surface of the colloidal particles through one or more available carboxylate moieties a and a biotin-modified probe contacted with the avidin or streptavidin-niodified surface forming a biotin-avidin (or biotin- streptavidin) linkage. Optionally, avidin or streptavidin may be attached in combination with another protein, such as BSA, and optionally be crosslinked. Probes having an amine, hydroxyl, or carboxylic acid functional group can be attached through water-soluble carbodiimide coupling reagents, such as EDC (l-ethyl-3 -(3 -dimethyl aminopropyl)carbodiimide), or other coupling agents well known in the art, which couples carboxylic acid functional groups with amine groups, hydroxyl groups, and/or other carboxylic acid functional groups.
[0067] Nucleotides attached to a variety of functional groups may be commercially obtained (for example, from Molecular Probes, Eugene, Oreg.; Quiagen (Operon), Valencia, Calif.; and IDT (Integrated DNA Technologies), Coralville, Iowa) and incorporated into oligonucleotides or polynucleotides. Biotin-modified nucleotides are commercially available (for example, from Pierce Biotechnology, Rockford, 111., or Panomics, Inc. Redwood City, Calif.) and modified nucleotides can be incorporated into nucleic acids during conventional amplification techniques. Oligonucleotides may be prepared using commercially available oligonucleotide synthesizers (for example, Applied Biosystems, Foster City, Calif). Additionally, modified nucleotides may be synthesized using known reactions, such as for example, those disclosed in, Nelson, P., Sherman-Gold, R, and Leon, R, "A New and Versatile Reagent for Incorporating Multiple Primary Aliphatic Amines into Synthetic Oligonucleotides," Nucleic Acids Res., 17:7179-7186 (1989) and Connolly, B., Rider, P. "Chemical Synthesis of Oligonucleotides Containing a Free Sulfhydryl Group and Subsequent Attachment of Thiol Specific Probes," Nucleic Acids Res., 13:4485-4502 (1985). Alternatively, nucleotide precursors may be purchased containing various reactive groups, - such as biotin, hydroxyl, sulfhydryl, amino, or carboxyl groups. After oligonucleotide synthesis, colloidal particles may be attached using standard chemistries. Oligonucleotides of any desired sequence, with or without reactive groups for colloidal particle attachment, may
also be purchased from a wide variety of sources (for example, Midland Certified Reagents, Midland, Tex.).
[0068] Probes, such as polysaccharides, may also be attached to colloidal particles, for example, through methods disclosed in Aslam, M. and Dent, A., Bioconjugation: Protein Coupling Techniques for the Biomedical Sciences, Grove's Dictionaries, Inc., 229, 254 (1998). Such methods include, but are not limited to, periodate oxidation coupling reactions and bis-succinimide ester coupling reactions.
[0069] The following paragraphs include further details regarding exemplary applications of colloidal particle-probes species. It will be understood that numerous additional specific examples of applications that utilize colloidal particle-probes species can be identified using the teachings of the present specification. One of skill in the art will recognize that many interactions between polypeptides and their target molecules can be detected using colloidal particle-labeled polypeptides. In one group of exemplary applications, colloidal particle- labeled antibodies (i.e., antibodies bound to a colloidal particle) are used to detect interaction of the colloidal particle-labeled antibodies with antigens. It will be understood that such immunoassays can be performed using known methods such as, for example, ELISA assays, Western blotting, or protein arrays, utilizing the colloidal particle-labeled antibody or colloidal particle-labeled secondary antibody, in place of a primary or secondary antibody labeled with an enzyme or a radioactive compound.
[0070] Another group of exemplary methods, uses colloidal particle probes to detect a target nucleic acid. Such a method is useful, for example, for detection of infectious agents within a clinical sample, detection of an amplification product derived from genomic DNA or RNA or message RNA, or detection of a gene (cDNA) insert within a clone. For certain methods aimed at detection of a target polynucleotide, an oligonucleotide probe is synthesized using methods known in the art. The oligonucleotide probe then is used to functionalize a colloidal particle to produce a colloidal particle-labeled oligonucleotide probe. The colloidal particle-labeled oligonucleotide probe is used in a hybridization reaction to detect specific binding of the colloidal particle-labeled oligonucleotide probe to a target polynucleotide. For example, the colloidal particle-labeled oligonucleotide probe can be used in a Northern blot or a Southern blot reaction. Alternatively, the colloidal particle-labeled oligonucleotide probe can be applied to a reaction mixture that includes the target polynucleotide associated with a solid support, to capture the colloidal particle-labeled oligonucleotide probe. The captured colloidal particle-labeled oligonucleotide probe can then be detected using fluorescence spectroscopy, with or without first being released from the
solid-support. Detection of the captured colloidal particle-labeled oligonucleotide probe can be amplified by first dissolving the isolated hybridized entity, wherein the monomelic BMSB are released into solution. Because the fluorescence particles used in this method are composed of a huge number of fluorescence molecules (e.g., Zn-BMSB), the approach allows for detection of small amounts of target analyte, down to about 5 aM (10"18 M).
[0071] In the methods of the invention, a sample includes a wide variety of analytes that can be analyzed using the colloidal particles described herein. For example, a sample can be an environmental sample and includes atmospheric air, ambient air, water, sludge, soil, and the like. In addition, a sample can be a biological sample, including, for example, a subject's breath, saliva, blood, urine, feces, various tissues, and the like.
[0072] Commercial applications for the invention methods employing the colloidal particles described herein include environmental toxicology and remediation, biomedicine, materials quality control, monitoring of food and agricultural products for the presence of ■ pathogens, anesthetic detection, automobile oil or radiator fluid monitoring, breath alcohol analyzers, hazardous spill identification, explosives detection, fugitive emission identification, medical diagnostics, fish freshness, detection and classification of bacteria and microorganisms both in vitro and in vivo for biomedical uses and medical diagnostic uses, monitoring heavy industrial manufacturing, ambient air monitoring, worker protection, emissions control, product quality testing, leak detection and identification, oil/gas petrochemical applications, combustible gas detection, H2S monitoring, hazardous leak detection and identification, emergency response and law enforcement applications, illegal substance detection and identification, arson investigation, enclosed space surveillance, utility and power applications, emissions monitoring, transformer fault detection, food/beverage/agriculture applications, freshness detection, fruit ripening control, fermentation process monitoring and control applications, flavor composition and identification, product quality and identification, refrigerant and fumigant detection, cosmetic/perfume/fragrance formulation, product quality testing, personal identification, chemical/plastics/pharmaceutical applications, leak detection, solvent recovery effectiveness, perimeter monitoring, product quality testing, hazardous waste site applications, fugitive emission detection and identification, leak detection and identification, perimeter monitoring, transportation, hazardous spill monitoring, refueling operations, shipping container inspection, diesel/gasoline/aviation fuel identification, building/residential natural gas detection, formaldehyde detection, smoke detection, fire detection, automatic ventilation control applications (cooking, smoking, etc.), air intake monitoring, hospital/medical
anesthesia and sterilization gas detection, infectious disease detection and breath applications, body fluids analysis, pharmaceutical applications, drug discovery, telesurgery, and the like.
[0073] Another application for the sensor-based fluid detection device in engine fluids is an oil/antifreeze monitor, engine diagnostics for air/fuel optimization, diesel fuel quality, volatile organic carbon measurement (VOC), fugitive gases in refineries,, food quality, halitosis, soil and water contaminants, air quality monitoring, fire safety, chemical weapons identification, use by hazardous material teams, explosive detection, breathalyzers, ethylene oxide or anesthetics detectors.
EXAMPLES
[0074] Solvents and all other chemicals were obtained from commercial sources and used as received unless otherwise noted. AU deuterated solvents were purchased and used as received from Cambridge Isotopes Laboratories. 1H and 13C NMR spectra were obtained using a Varian Mercury 300 MHz or a Varian INOVA 400 MHz FT-NMR spectrometers. Infrared spectra of solid samples were obtained on a Thermo Nicolet Nexus 670 FT-IR spectrometer as KBr pellet. Diffuse reflectance spectra were obtained on a Varian Gary 5000 UV-Vis-NIR spectrophotometer. Emission spectra were obtained on a Jobin Yvon SPEX Fluorolog fiuorometer using quartz cells (10 x 4 mm light path). Electrospray ionization mass spectrometric (ESI-MS) spectra were obtained on a Micromass Quatro II Triple Quadrupole mass spectrometer, and all peaks are cosnsitent with a natural abundance isotopic distribution patterns. Elemental analyses were obtained from Quantitative Technologies Inc., Whitehouse, NJ. All scanning electron microscopy (SEM) images and energy dispersive X- ray (EDX) spectra were obtained using a Hitachi S-4500 cFEG SEM (Electron Probe Instruments Center (EPIC), NUANCE, Northwestern University) equipped with an Oxford Instruments EDS system. All optical and fluorescence microscopy images were obtained using a Zeiss Axiovert IOOA inverted optical/fluorescence microscope (Thomwood, NY) equipped with a Penguin 600CL digital camera (HQ FITC/Boρidy/Fluo3/Di o/EGFP and HQ Texas Red filter sets were used for green and red emission, respectively). Particle size, size distribution, and ζ-potential measurements in solution were performed with a Zetasizer Nano- ZS.
SYNTHESIS OF BIS-METALLIC SCHIFF BASE (BMSB) COMPOUNDS
[0075] (S) 3,3'-difoϊmyl-2,2'-dihydroxy-l,l '-binaphthyl (200-mg, 0.585 mmol), which was synthesized according to the literature procedures (Zhang et al., J. Org. Chem. 66:481 (2001)), and 3-amino-4-hydroxy-benzoic acid (198 mg, 1.29 mmol) were mixed in ethanol (15 mL). The resulting solution was refluxed for 1 h. During this time, a yellow product precipitated. The precipitate product (BSB SIa) was filtered and washed with hot ethanol (85% yield). 1H NMR (300 MHz, DMSO-^, 25 °C): δ 13.40 (s, 2H, OH), 12.70 (br, 2H, CO2H), 10.65 (s, 2Η, OH), 9.37 (s, 2Η, CH=N), 8.51 (s, 2H), 8.04 (s, 2H), 8.02 (d, J- 8.2 Hz, 2H), 7.76 (d, J= 8.4 Hz, 2H), 7.36 (m, 4H), 7.07 (d,J= 8.1 Hz, 2H), 7.04 (d, J= 8.4 Hz, 2H). 1H NMR (300 MHz, pyridine-^, 25 0C): δ 9.36 (s, 2H, CH=N), 8.62 (d, J= 1.2 Hz, 2H), 8.36 (dd, J= 8.7 Hz, J= 1.2 Hz, 2H), 8.26 (s, 2H), 8.09 (m, 2H), 7.64 (m, 2H), 7.38 (m, 4H)5 7.31 (d, J= 8.7 Hz, 2H). 13C(1H) NMR (100.7 MHz, DMSO-^5 25 °C): δ.167.03 (CO2H)5 163.21 (C=N)5 155.76 (C-OH), 154.47 (C-OH)5 135.16, 134.88, 134.62, 130.02, 129.23, 128.64, 127.24, 124.28, 123.41, 122.14, 121.45, 120.85, 116.37, 116.26. 13C(1H) NMR (100.7 MHz, pyridine-dj, 25 °C): δ 169.35 (CO2H), 163.47 (C=N), 157.72 (C-OH), 156.45 (C-OH), 137.05, 136.61, 135.50, 131.52, 130.68, 130.22, 129.49, 128.83, 126.04, 124.51, 123.05, 122.99, 118.29, 117.67. Anal. Calcd for C36H24N2O8: C, 70.58; H, 3.95; N, 4.57. Found: C, 70.38; H, 4.02; N, 4.34. ESI-MS (m/z, DMSO/CH2C12): calcd for [SIa + H+]+ 5 613.2; found, 613.1. IR (KBr pellet, cm"1): 1684s, 1615s, 1596s, 1506m, 1438m, 1412w, 1384w, 1363w, 134Ow, 1293m, 1270m, 1213w, 1185w, 1152m, 1119m, 1043w, 98Ow, 952m, 905w, 889w, 832w, 776m, 757m, 63Ow.
(Compound SIb)
[0076] BSB SIb was synthesized using the same method as for SIa, except 2-amino- phenol was used instead of 3-amino-4-hydroxy-benzoic acid (90% yield). 1H NMR (300 MHz, DMSO-rftf, 250C): δ 13.59 (s, 2H, OH), 9.78 (s, 2H, OH), 9.29 (s, 2H, CH=N), 8.43 (s, 2H)5 8.04 (m, 2H), 7.47 (d, J= 7.5 Hz, 2H), 7.35 (m, 4H), 7.15 (t, J= 7.5 Hz3 2H), 7.06 (m, 2H), 6.97 (d, J= 7.6 Hz, 2H), 6.91 (t, J= 7.5 Hz, 2H). 1H NMR (300 MHz, pyridine-^, 25 0C): δ 14.27 (s, 2H), 12.04 (br, 2H), 9.32 (s, 2H, CH=K), 8.28 (s, 2H), 8.02 (m, 2H>, 7.60 (m, 2H), 7.50 (d, J= 7.8 Hz, 2H), 7.36 (m, 4H), 7.22 (m, 4H>, 7.01 (m, 2H). 13C(1H) NMR (100.7 MHz, DMS(M?, 25 0C): δ 162.05 (ON), 154.54 (C-OH), 151.57 (C-OH), 135.01, 134.64, 134.26, 129.12, 128.53, 128.45, 127.22, 124.25, 123.31, 121.53, 119.76, 119.65, 116.68, 116.29. Anal. Calcd for C34H24N2O4: C, 77.85; H, 4.61; N, 5.34. Found: C, 77.71; H, 4.58; N, 5.33. ESI-MS (m/z, DMSO/CH2C12): calcd for [SIb + H+]+, 525.2; found, 525.4.
[0077] Zn-BMSB 2a: BSB SIa, synthesized as decribed above, (5 mg, 0.008 mmol) and Zn(OAc)2 (3 mg, 0.016 mmol) were mixed in DMF (3 mL). The color of the solution changed immediately from yellow to red. Diethyl ether was added to precipitate the product as an orange powder (84% yield). The precipitate product was separated from supernatant and washed with diethyl ether (84% yield). 1H NMR (300 MHz, pyridine-Jj, 250C): δ 9.60 (s, 2H, CH=N), 9.11 (d, J= 1.8 Hz, 2H), 8.58 (dd, J= 8.4 Hz, J= 1.8 Hz, 2H), 8.20 (s, 2H), 8.15 (d, J= 7.8 Hz, 2H), 7.79 (d, J= 8.4 Hz, 2H), 7.49 (d, J= 8.4 Hz, 2H), 7.35 (t, J = 7.6 Hz, 2H), 7.28 (t, J= 7.6 Hz, 2H). 13C(1H) NMR (100.7 MHz, pyridine-^, 25 0C): δ 171.22 (CO2H), 169.81 (C-O), 166.21 (C-O), 159.45 (C=N), 139.02, 136.79, 135.08, 132.98, 131.02, 130.27, 128.12, 126.13, 125.20, 124.74, 120.96, 120.12, 117.97, 116.65. ESI-MS (m/z, pyridine/CH2Cl2): calcd for [SIa - 4H+ + 2Zn2+ + 2 pyridine + H+J+, 895.1; found, 894.9; calcd for [SIa - 4H+ + 2Zn2+ + pyridine + H+J+, 816.0; found, 816.0. IR (KBr pellet, cm4): 1659s, 1609s, 1588s, 1539w, 1506w, 1491m, 1425m, 1383s, 1339m, 1298m, 1223w, 1198w, 1173w, 1151w, 1121m, 1104m, 1061w, 1044w, 1024w, 958m, 898w, 843m, 788m, 748m, 663m, 478w.
[0078] Cu-BMSB 2b: 2b was prepared using the same method as for 2a, except Cu(OAb)2(H2O) was used instead OfZn(OAc)2. A brown powder was obtained in 86% yield. ESI-MS {ink, pyridine/CH2Cl2): calcd for [SIa - 4H+ + 2Cu2+ + 2 pyridine + H+J+, 893.1; found, 892.9. IR (KBr pellet, cm"1): 1653s, 1604s, 1585s, 1539w, 1522w, 1491m, 1427m, 1386s, 1369s, 1340m, 13Q6m, 126Ow, 1225w, 1194w, 1173w, 115Ow, 1123m, 1102m, 106 Iw, 1044w, 1023w, 956m, 898w, 846m, 784m, 748m, 666m, 506w, 481 w.
[0079] X-ray crystal structure determination of 2b: A dark tabular crystal was mounted using oil on a glass fiber. Diffraction intensity data were collected with a Bruker SMART- 1000 CCD diffractometer equipped with a graphite-monochromated Mo Ka radiation source. The data collected were processed to produce conventional intensity data by the program SAINT-NT (Bruker). The intensity data were corrected for Lorentz and polarization effects. Absorption corrections were applied using the SADABS empirical method. The structures were solved by direct methods, completed by subsequent difference Fourier syntheses and refined by full matrix least-squares procedures, on F2. The disordered methanol was refined with a group anisotropic displacement parameter^ and occupancies adding to fully occupied. The remaining non-hydrogen atoms were refined anisotropically. Hydrogen atoms were included in idealized positions, except those on the disordered and partially occupied methanol, and the hydrogen atom on 05 (methanol), but not refined. The DMF was fixed to 1A occupied. All software and sources of scattering factors are contained in the SHELXTL program package (version 5.10, G. Sheldrick, Bruker- AXS, Madison, WI).
[0080] Ni-BMSB 2c: 2c was prepared using the same method as for 2a, except Ni(OAc)2-4(H2O) was used instead OfZn(OAc)2. A red powder was obtained in 82% yield. ESI-MS (m/z, pyridine/CH2Cl2): calcd for [SIa - 4H+ + 2Ni2+ + 2 pyridine + H+J+, 883.1; found, 882.8. IR (KBr pellet, cm"1): 1655s, 1608s, 1584s, 1545w, 1491m, 1419m, 1387s, 1339m, 1304m, 1263w, 1226w, 1193w, 1173w, 1151w, 1119m, 1104m, 1061w, 1048w, 1026w, 960m, 901 w, 841m, 786m, 749m, 668m, 517w, 479w.
[0081] 2d: 2d was. prepared using the same method as for 2a, except BSB SIb was used instead of BSB SIa. An orange powder was obtained in 81% yield. 1HNMR (300 MHz, pyridine-;/?, 25 °C): δ 9.54 (s, 2H, CH=N), 8.31 (s, 2Η), 8.07 (d, J= 8.4 Hz, 2H), 7.94 (d, J= 8.1 Hz, 2H), 7.80 (d,J= 8.1 Hz, 2H), 7.48 (d, J- 8.1 Hz, 2H), 7.40 (t, J= 7.4 Hz, 2H), 7.33 (t, J= 7.5 Hz, 2H), 7.24 (t, J= 7.5 Hz, 2H), 7.79 (t, J= 7.5 Hz, 2H). 13C(1H) NMR (100.7 MHz,
25 °C): δ 166.23 (C-O), 165.52 (C-O), 158.53 (ON), 138.86, 136.41, 135.70, 131.19, 130.69, 130.31, 128.01, 126.16, 126.07, 125.64, 120.90, 120.77, 115.69, 114.18. ESI-MS (m/z, pyridine/CH2Cl2): calcd for [SIb - 4H+ + 2Zn2+ + 2 pyridine + H+]+, 807.1; found, 806.9, calcd for [SIb - 4H+ + 2Zn2+ + pyridine + H+f, 728.1; found, 728.1.
COLLOIDAL PARTICLE FORMATION
[0082] Slow diffusion method: A precursor solution was prepared by mixing BMSB 2a-c (0.008 mmol) and M(OAc)2 (0.008 mmol, M = Zn, Cu, Ni) in pyridine (200 ~ 400 μL) (as an alternative way, by mixing BSB SIa (0.008 mmol) and M(OAc)2 (0.024 mmol, M = Zn, Cu, Ni)). Diethyl ether or pentane was allowed to slowly diffuse into the precursor solution. After 1 to 2 hours, micro-size spherical particles 3 form. Particle products were isolated and subsequently washed with toluene via centrifugation-redispersion cycles. Each successive supernatant was decanted and replaced with fresh toluene (74 to 86% yield).
[0083] Fast addition method: A precursor solution was prepared as described above. Diethyl ether or pentane (8 mL) was rapidly added into a precursor solution to form nano-size spherical particles 3. Products were isolated and washed as described above (85 ~ 92% yield).
[0084] IR spectra taken before and after formation of the particles show that the carboxylate groups are coordinating to metal ions as evidenced by a shift in CO stretching frequency from 1653 - 1659 cm"1 for the monomeric unbound forms (2a-c) to 1597 - 1605 cm"1 for the polymer particles (3a-c). 1H and 13C NMR spectra of diamagnetic 3a indicate coordination of the carboxylic acid groups to the metal center. The electrospray ionization mass spectra of 3b and 3c exhibit intense peaks associated with the metal-metalloligand repeat units, [2b - 2H+ + Cu2+ + (pyridine),, + H+J+ and [2c - 2H+ + Ni2+ + (pyridine),, + H+]+. The NMR spectra of 3b and 3c were not informative because of the paramagnetic nature of these complexes, and the mass spectrum of 3a did not yield a monomer ion. The measurement of Zeta potential of these particles reveals that particles are negatively charged (-12 mV), which is a result of the deprotonated carboxylate groups located on their surfaces.
[0085] Ancillary Iigands exchange reactions: The 1H NMR spectra of the methanol-^ and OMSO-dβ suspension of spherical particles 3a with ancillary Iigands L of pyridine and methanol respectively, show the peaks for free pyridine and methanol molecules, which are released from the metal upon replacement with methanol-^ and OMSO-dg, respectively. The elemental analysis measured before and after the exchange of ancillary Iigands L from pyridine to methanol, show a decreasing nitrogen content from 6.33 to 3.35%.
[0086] Zn-BMSB-Zn 3a: 1H NMR (300 MHz, pyridine-dj, 25 0C): δ 9.52 (s, 2H, CH=N), 9.28 (d, J= 1.5 Hz, 2H), 8.77 (dd, J= 8.4 Hz, J= 1.5 Hz, 2H), 8.10 (d, J= 8.1 Hz, 2H), 8.05 (s, 2H), 7.76 (d, J= 8.4 Hz, 2H), 7.50 (d, J= 8.4 Hz, 2H), 7.31 (t, J= 7.6 Hz, 2H), 7.24 (t, J= 7.6 Hz, 2H). 13C(1H) NMR (100.7 MHz, pyridine-^, 25 0C): δ 175.95 (CO2), 168.90 (C-O), 166.14 (C-O), 158.75 (C=N), 138.87, 134.65, 133.51, 131.01, 130.16, 127.91, 126.06,, 125.29, 124.67, 124.43, 120.81, 120.50, 119.72, 118.26. Anal. Calcd for Zn3(SIa - 6H)(ρyridine)3: C, 58.90; H, 3.20; N, 6.73. Found: C, 57.83; H, 3.10; N, 6.33. IR (KBr pellet, cm"1): 1605s, 1591sh, 1539m, 1506w, 1489w, 1465w, 1448m, 1425w, 1375s, 1341m, 1327m,
1299m, 1217m, 1194w, 1171w, 1148m, 1121m, 1069m, 1042m, 1015w, 955w, 894w, 842m, 787m, 749m, 698m, 663m, 636m, 478w, 419w.
[0087] Cu-BMSB-Cu 3b: ESI-MS (m/z, pyridme/CH2Cl2): calcd for [SIa - 6H+ + 3Cu2+ + 3 pyridine + H+J+, 1033.0; found, 1032.7, calcd for [SIa - 6H+ + 3Cu2+ + 2 pyridine + H+]+, 954.0; found, 954.0. Anal. Calcd for Cu3(SIa - 6H)(H2O)2(pyridine)3: C, 57.22; H, 3.48; N, 6.54. Found: C, 57.69; H, 2.96; N, 6.47. IR (KBr pellet, cm"1): 1602s, 1589sh, 1539m, 1507w, 149Ow, 1466w, 1449m, 1425w, 1369s, 1342m, 1325m, 1262w, 1217m, 119Ow, 1172w, 1148m, 1124m, 1069m, 1043m, 1017w, 955w, 897w, 846m, 783m, 748m, 696m, 671m, 639m, 504w, 479w, 419w.
[0088] Ni-BMSB-Ni 3c: ESI-MS (m/z, pyridine/CH2Cl2): calcd for [SIa - 6H+ + 3Ni2+ + 4 pyridine + H+]+, 1097.1; found, 1097.0. Anal. Calcd for Ni3(SIa - 6H)(H2O)2(pyridine)3: C, 58.01; H, 3.53; N, 6.63. Found: C, 58.08; H, 3.28; N, 6.57. IR (KBr pellet, cm'1): 1597s, 1589sh, 1542m, 1507w, 1497w, 1465w, 1448m, 1429w, 1385s, 1369m, 1343m, 1324m, 1269w, 1217m, 1192w, 1172w, 1149m, 1125m, 1070m, 1042m, 1017w, 951w, 897w, 856m, 786m, 757m, 693m, 639w, 516w, 494w, 419w. There are inherent difficulties in formulating
the exact number of pyridine and water in particle 3a-c due to the possibility of exchange with other molecules.
Detection Assay Using Colloidal Particles
[0089] Preparation of the Probes: For the magnetic probe preparation (MMP), 5 '- amino-functionalized DNA (5'-NH2-AAA AAA AAA ATC CTT ATC AAT-3') (SEQ. ID NO: 1) was directly linked to tosyl-activated MMPs using the procedure recommended by Dynal Biotech Inc. For the fluorescence probe preparation, 3 '-amino-functionalized DNA (5'-ATT TAA CAA TAA TCC AAA AAA AAA A-NH2-3') (SEQ. ID NO: 2) was directly attached to the fluorescence particles, which have many carboxylic groups at the surface, by using N-ethyl-N'-(3-dimethylaminoproρyl)carbodiimide (EDC) as a linker. FIG. 9 shows a schematic of the structures of both the MMP and the colloidal particles. The colloidal particles that were used had an average diameter of 1.60 ± 0.47 μm (s.d., n=100).as determined by SEM.
[0090] Fluorescence Amplification Based Bioassay for DNA: The fluorescence amplification based bioassay method was tested with oligonucleotide associated with the anthrax lethal factor (5'-GGA TTA TTG TTA AAT ATT GAT AAG GAT-3') (SEQ. ID. NO: 3) in 0.3 M PBS buffer containing 0.025% Tween 20 as a target over a range of 5 aM (10"18) to 50 fM (10"15 M). In a typical assay, a sample solution (50 μL) with a set of target DNA concentration was added to a 50 μL of MMP probes functionalized with a single-strand DNA (SEQ. ID NO: 1) to capture the target DNA, and the solution was shaken on an orbital shaker at 50° C for 15 minutes and at 20°C for 45 minutes. The fluorescence particles functionalized with a single-strand DNA (SEQ. ID NO: 2) to form a sandwich structure with the MMP probes that have captured the target DNA (e.g., SEQ. ID NO: 3) were then added to the solution. This solution was vigorously stirred at 20° C for 2 hours. The magnetic separator was used to concentrate both unreacted magnetic particles and magenetic particles which captured the target DNA and fluorescence colloidal particles. These particles were vigorously washed six times with 0.3 M PBS buffer containing 0.025% Tween 20 to remove any unreacted fluorescence colloidal particles. After the copious washing step, the reacted fluorescence colloidal particles were dissolved in pyridine (100 μL). The solution of particles dissolved with pyridine was studied by fluorescence spectroscopy. The solution was excited at 420 nm and fluorescence emission was measured at 600 nm. In each experiment, a negative control (no target DNA in the reaction mixture) was run for comparison. The area of the spectra from 580 to 615 nm was integrated. AU target concentrations over the 5 aM to 50 fM concentration range was differentiated from negative control (FIG. 10 A). The assay
exhibits a linear relationship between target concentration and fluorescence intensity over a four order of magnitude concentration range (FIG. 10 B).
[0091] The foregoing description of the present invention has been presented for purposes of illustration and description. The description is not intended to limit the invention to the embodiment disclosed herein. Variations and modifications commensurate with the above teachings, and the skill or knowledge of the relevant art, are within the scope of the present invention.
Claims
1. A colloidal particle having a formula (I) or (II):
wherein R1 and R3 are independently selected from the group consisting of H, hydroxyl, C1-8alkyl, OC1-8 alkyl, C1-8heteroalkyl, OCi-8heteroalkyl, P(R2)2, aryl, heteroaryl; R2 is the same or different and is selected from aryl or heteroaryl; M and M' are independently selected from the group consisting of Zn, Cu, Mn, Pb, Ni, Co, Cd, and Cr; L is a ligand selected from the group consisting of pyridine, methanol, acetate, dimethylsulfoxide, dimethylformamide, acetone, water, chloride, fluoride, iodide, bromide, and hydroxide; x is an integer from 0 to 3; n is an integer from 0 to 5; and m is an integer from about 100 to about 10,000.
2. The colloidal particle of claim 1, wherein M and M' are the same.
3. The colloidal particle of claim 1 , wherein M and M' are different.
4. The colloidal particle of claim 1, wherein the diameter of the particle is about lμm to about 5 μm.
5. The colloidal particle of claim 1, wherein the diameter of the particle is about 150 nm to less than 1 μm.
7. A method of synthesizing a colloidal particles having a formula (I) or (II):
comprising the steps of: a) mixing a metal salt having a formula M'(O2CCH3)y and a compound of formula (III) or (IV):
wherein R1 and R3 are independently selected from the group consisting of H, hydroxy., Ci-8alkyl, OC1-S alkyl, Q-sheteroalkyl, OC1-8heteroalkyl, P(R2)2, aryl, heteroaryl; R2 is the same or different and is selected from aryl or heteroaryl; heteroaryl M and M' are independently selected from the group consisting of Zn, Cu, Mn, Pb, Ni, Co, Cd, and Cr; L is null or selected from the group consisting of pyridine, methanol, acetate, dimethylsulfoxide, dimethylformamide, acetone, water, chloride, fluoride, iodide, bromide, and hydroxide; x is an integer from O to 3; and y is an integer from 1 to 4; and b) adding a nonpolar solvent to the product of step (a) to form the colloidal particles.
8. The method of claim 7, wherein the nonpolar solvent is selected from the group consisting of pentane, diethyl ether, toluene, hexanes, and benzene.
9. The method of claim 7, further comprising washing the colloidal particles with a nonpolar solvent.
10. The method of claim 7, wherein the ratio of the metal salt to the compound of formula (III) or (IV) is about 1:1 to about 20:1.
11. The method of claim 7, wherein the adding of the nonpolar solvent is rapid and the resulting colloidal particles have a diameter of about 100 nm to less than 1 μm.
12. The method of claim 7, wherein the adding of the nonpolar solvent is slow and the resulting colloidal particles have a diameter of about 1 μm to about 5 μm.
13. The method of claim 7, wherein the colloidal particles are disassembled by the addition of pyridine to form the metal salt and the compound of formula (I) or (II).
14. The method of claim 7, further comprising adding a metal salt having a formula M"(O2CCH3)Z to the colloidal particles to form a compound having a formula:
15. The method of claim 14, wherein the ratio of the metal salt having a formula M"((O2CCH3)Z to compound of formula (I) or (II) is about 1:1 to about 30:1.
16. A method of determining the presence or concentration of an analyte in a sample comprising using a sandwich assay comprising a colloidal particle of claim 1 which further comprises a tag specific for the analyte.
17. The method of claim 16, wherein the sandwich assay comprises: a) mixing (1) a magnetic microparticle (MMP) having a tag specific for the analyte, (2) a colloidal particle of claim 1 further modified with a second tag specific for the analyte, and (3) the sample having the analyte to form a sandwich complex MMP-analyte- colloidal particle; b) isolating the sandwich complex from the sample via a magnet; c) adding pyridine to the isolated sandwich complex of step (b) to form a solution; d) measuring the fluorescence of the resulting solution from step (c); and e) correlating the fluorescence measured in step (d) to the presence or concentration of the analyte.
18. The method of claim 16, wherein the analyte is a nucleic acid, protein, peptide, or metal ion.
19. The method of claim 16, wherein M and M ' of the colloidal particle are Zn.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US68578605P | 2005-05-31 | 2005-05-31 | |
US60/685,786 | 2005-05-31 | ||
US77763806P | 2006-02-28 | 2006-02-28 | |
US60/777,638 | 2006-02-28 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2007053181A2 true WO2007053181A2 (en) | 2007-05-10 |
WO2007053181A3 WO2007053181A3 (en) | 2007-08-09 |
Family
ID=38006340
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2006/020966 WO2007053181A2 (en) | 2005-05-31 | 2006-05-31 | Chemically tailorable nanoparticles realized through metal-metalloligand coordination chemistry |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2007053181A2 (en) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009133229A1 (en) | 2008-04-29 | 2009-11-05 | Consejo Superior De Investigaciones Científicas | Metallo-organic system for the encapsulation and release of compounds of interest, method for obtaining same and uses thereof |
EP2287611A1 (en) * | 2009-07-31 | 2011-02-23 | Fujifilm Corporation | Detecting method and dielectric particle containing magnetic material employed in the detecting method |
CN103323443A (en) * | 2013-07-11 | 2013-09-25 | 中国科学院化学研究所 | Application of infinite coordination polymer with visual alcoholic strength sensing function |
JP2015038052A (en) * | 2013-08-19 | 2015-02-26 | 国立大学法人 千葉大学 | Bisaminoimine ligand and catalyst having binaphthol skeleton |
CN107602413A (en) * | 2017-09-13 | 2018-01-19 | 哈尔滨理工大学 | Binol diform contractings o-aminophenol class schiff bases and its synthetic method and application |
CN110938232A (en) * | 2019-08-26 | 2020-03-31 | 兰州理工大学 | Metal ion flame-retardant complex with Schiff base structure and preparation method thereof |
US11452967B2 (en) | 2017-07-17 | 2022-09-27 | Zymergen Inc. | Metal-organic framework materials |
WO2023008352A1 (en) * | 2021-07-29 | 2023-02-02 | 富士フイルム株式会社 | Coloring composition, film, optical filter, solid-state imaging device, image display device, and dye multimer |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107721876B (en) * | 2017-09-13 | 2020-02-21 | 哈尔滨理工大学 | Binol-diform condensed amino acid Schiff base and synthesis method and application thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020187347A1 (en) * | 1997-03-12 | 2002-12-12 | Wm. Marsh Rice University | Multi-layer nanoshells |
WO2004046164A2 (en) * | 2002-05-10 | 2004-06-03 | Engeneos, Inc. | Unique recognition sequences and methods of use thereof in protein analysis |
-
2006
- 2006-05-31 WO PCT/US2006/020966 patent/WO2007053181A2/en active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020187347A1 (en) * | 1997-03-12 | 2002-12-12 | Wm. Marsh Rice University | Multi-layer nanoshells |
WO2004046164A2 (en) * | 2002-05-10 | 2004-06-03 | Engeneos, Inc. | Unique recognition sequences and methods of use thereof in protein analysis |
Non-Patent Citations (2)
Title |
---|
LAKOWICZ, JOSEPH R. ET AL: "Advances in surface-enhanced fluorescence" PROCEEDINGS OF SPIE-THE INTERNATIONAL SOCIETY FOR OPTICAL ENGINEERING , 5327(PLASMONICS IN BIOLOGY AND MEDICINE), 10-28 CODEN: PSISDG; ISSN: 0277-786X, 2004, XP009084583 * |
OH, MOONHYUN ET AL: "Chemically tailorable colloidal particles from infinite coordination polymers" NATURE (LONDON, UNITED KINGDOM) , 438, 651-654 CODEN: NATUAS; ISSN: 0028-0836, 7068, XP002435668 * |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009133229A1 (en) | 2008-04-29 | 2009-11-05 | Consejo Superior De Investigaciones Científicas | Metallo-organic system for the encapsulation and release of compounds of interest, method for obtaining same and uses thereof |
EP2287611A1 (en) * | 2009-07-31 | 2011-02-23 | Fujifilm Corporation | Detecting method and dielectric particle containing magnetic material employed in the detecting method |
US8456158B2 (en) | 2009-07-31 | 2013-06-04 | Fujifilm Corporation | Detecting method and dielectric particles containing magnetic material employed in the detecting method |
CN103323443A (en) * | 2013-07-11 | 2013-09-25 | 中国科学院化学研究所 | Application of infinite coordination polymer with visual alcoholic strength sensing function |
CN103323443B (en) * | 2013-07-11 | 2015-11-11 | 中国科学院化学研究所 | A kind of application with the unlimited coordination polymer of visual alcoholic strength sensing function |
JP2015038052A (en) * | 2013-08-19 | 2015-02-26 | 国立大学法人 千葉大学 | Bisaminoimine ligand and catalyst having binaphthol skeleton |
US11452967B2 (en) | 2017-07-17 | 2022-09-27 | Zymergen Inc. | Metal-organic framework materials |
CN107602413A (en) * | 2017-09-13 | 2018-01-19 | 哈尔滨理工大学 | Binol diform contractings o-aminophenol class schiff bases and its synthetic method and application |
CN107602413B (en) * | 2017-09-13 | 2019-08-20 | 哈尔滨理工大学 | Binol-diform contracting o-aminophenol class schiff bases and its synthetic method and application |
CN110938232A (en) * | 2019-08-26 | 2020-03-31 | 兰州理工大学 | Metal ion flame-retardant complex with Schiff base structure and preparation method thereof |
CN110938232B (en) * | 2019-08-26 | 2021-06-01 | 兰州理工大学 | Metal ion flame-retardant complex with Schiff base structure and preparation method thereof |
WO2023008352A1 (en) * | 2021-07-29 | 2023-02-02 | 富士フイルム株式会社 | Coloring composition, film, optical filter, solid-state imaging device, image display device, and dye multimer |
Also Published As
Publication number | Publication date |
---|---|
WO2007053181A3 (en) | 2007-08-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2007053181A2 (en) | Chemically tailorable nanoparticles realized through metal-metalloligand coordination chemistry | |
JP4705586B2 (en) | Synthetic organic-inorganic nanocluster | |
US20100240870A1 (en) | Composite organic-inorganic nanoclusters | |
Augustus et al. | A review of synthesis, characterization and applications of functionalized dendrimers | |
TWI360657B (en) | External modification of cmoposite organic inorgan | |
Larmour et al. | Surface enhanced optical spectroscopies for bioanalysis | |
Zou et al. | Ultrasensitive detection of HIV DNA with polymerase chain reaction–dynamic light scattering | |
AU2009317878B2 (en) | Analyte detection assay | |
Gaillard et al. | Peptide nucleic acid–nanodiamonds: covalent and stable conjugates for DNA targeting | |
Chen et al. | Fishing unfunctionalized SERS tags with DNA hydrogel network generated by ligation-rolling circle amplification for simple and ultrasensitive detection of kanamycin | |
US7427513B2 (en) | Surface modification of metals for biomolecule detection using surface enhanced Raman scattering (SERS) | |
Ren et al. | “Three-in-one” Zr-MOF multifunctional carrier-mediated fluorescent and colorimetric dual-signal readout biosensing platform to enhance analytical performance | |
Tobias et al. | Polystyrene microparticles with convergently grown mesoporous silica shells as a promising tool for multiplexed bioanalytical assays | |
Yi et al. | Plasmonic colloidosome-based multifunctional platform for bacterial identification and antimicrobial resistance detection | |
Murugan et al. | Core–Shell Nanostructured Fe3O4–Poly (styrene-co-vinylbenzyl chloride) Grafted PPI Dendrimers Stabilized with AuNPs/PdNPs for Efficient Nuclease Activity | |
Sethi et al. | Understanding the mechanism of amino acid-based Au nanoparticle chain formation | |
Sikka et al. | Aqueous-phase biofunctionalized NH2-MIL-53 (Al) MOF for biosensing applications | |
Lawrence et al. | Pentafluorophenyl ester-functionalized nanoparticles as a versatile platform for selective and covalent inter-nanoparticle coupling | |
Li et al. | orthogonal adsorption of carbon dots and DNA on nanoceria | |
Liu et al. | Atomic force microscopy imaging study of aligning DNA by dumbbell-like Au–Fe3O4 magnetic nanoparticles | |
Grillo | Development of a novel assay for drugs of abuse based on Molecularly Imprinted Polymers as synthetic antibodies | |
Beyene et al. | Characterization of iron oxide magnetic nanoparticles for extraction of harar coffee (coffea arabica L.) genomic DNA | |
TW200535246A (en) | Composite organic-inorganic nanoclusters | |
Nouri et al. | Dual-functional ratiometric fluorescence sensor based on silica spheres for highly selective detection of Hg2+ and Fe3+ | |
Elgazar et al. | Novel metal–organic framework biosensing platform for detection of COVID-19 RNA |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
NENP | Non-entry into the national phase in: |
Ref country code: DE |
|
NENP | Non-entry into the national phase in: |
Ref country code: RU |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 06844112 Country of ref document: EP Kind code of ref document: A2 |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 06844112 Country of ref document: EP Kind code of ref document: A2 |